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Abstract  
Background: Wide access to antiretroviral therapy (ART) has substantially improved the prognosis of 
patients living with HIV/AIDS (PLHIV). However, in resource-limited countries, sustaining ART 
programs to prevent drug resistance and treatment failure and to maximize the existing human 
resources is still challenging. In 2010, Vietnam had 254,000 PLHIV and 52,000 people accessed ART. 
Viral load (VL) testing has not been routinely performed for monitoring treatment failures due to the 
high cost and the necessity of advanced laboratory equipment. Peer support has been proven to improve 
quality of life, reduce stigma and to improve adherence to treatment. However, there is little known 
about the impact of peer adherence support on ART outcomes. The overall aim of this study was to 
assess the impact of peer support on virologic and immunologic treatment outcomes and mortality 
among HIV-infected patients by monitoring routinely a simple- and low- cost VL in a cluster 
randomized controlled trial in Quang Ninh, Vietnam. The primary outcome was virologic failure rate 
between intervention and control group.  
Methods: A total of 640 HIV-infected patients recruited from 59 clusters (communes) were 
randomized into either intervention or control group. Both groups received first-line ART regimens 
according to the National Treatment Guidelines and were followed up for 24 months. Viral load 
(ExaVir
TM
 Load) and CD4 counts were measured every 6 months. Patients in the intervention group 
received enhanced adherence support by 14 peer supporters. Survival analyses with Kaplan-Meier 
curve and Cox proportional hazard model were used to identify survival rate and risk factors for deaths. 
Causes of death were assessed through medical records and verbal autopsy questionnaire. Cluster 
longitudinal and survival analyses with intention-to-treat were used to study time to virologic failure 
and CD4 trends and to compare between the intervention and control groups. At baseline, we 
monitored the spread of infection and prevalence of transmitted drug resistance mutations (TDRMs) by 
analyzing 63 1000bp pol-gene sequences generated from 63 treatment-naïve HIV-1 CRF01_AE 
patients. Through the cohort, we determined the feasibility, sensitivity and specificity of ExaVir Load 
in 605 HIV treatment-naïve patients and compared the correlation and agreement of 60 samples 
between Roche Cobas TaqMan
®
 VL and ExaVir Load.  
Results: After 24 months of follow-up, 78% of the patients remained in the study, mortality rate was 
11% (6.4/100 person-years), cumulative virologic failure rate (VL >1,000 copies/ml) was 7.2% and the 
median CD4 increase was 286 cells/µl. There were no significant differences between intervention and 
control groups in virologic failure rates (VL >1,000 copies/ml) [6.9% vs 7.5%, respectively, RR 0.93; 
(95%CI: 0.13-6.54), p=0.94], in the time to virologic failure [HR 1.0; (95%CI 0.5-1.7), p=0.94], in 
CD4 trends [Coeff. (95%CI: 0.2(-0.6;-0.9), p=0.69] and in mortality (Log-rank p=0.79). Risk factors 
for virologic failure were ART-non-naïve status [aHR 6.9;(95%CI 3.2-14.6); p<0.01]; baseline VL 
>100,000 copies/ml [aHR 2.3;(95%CI 1.2-4.3); p<0.05] and incomplete adherence (self-reported 
missing more than one dose during 24 months) [aHR 3.1;(95%CI 1.1-8.9); p<0.05]. From the cohort of 
605 ART-treatment naïve patients, we found the virologic suppression rate (VL <200 copies/ml) after 
24 months was 64% (intention-to-treat) and 94% among patients assessed with VL (on-treatment). 
Tuberculosis (TB) was the most common cause of death (40%). Risk factors for AIDS-related death 
were age >35 years, clinical stage 3 or 4, body mass index (BMI) <18 kg/m2, CD4 count <100/μl, 
haemoglobin level <100 g/l, and plasma VL >100,000 copies/ml. The TDRMs including Y181C, 
L210W, L74I and V75M were found in 4/63 patients (6.3%). Phylogenetic analysis for calculating the 
time of the most recent common ancestor (tMRCA) was shown in two distinct groups: the small group 
(n=3) had tMRCA in year 1997.5 and the larger group had tMRCA in 1989.8.  The ExaVir Load and 
the Roche Cobas TaqMan showed a strong correlation (r
2
 =0.97), high agreement (log difference 
=0.34; 95% CI -0.35;1.03), high sensitivity (98%) and high specificity (100%).  
Conclusions: Enhanced adherence intervention by peer support had no impact on virologic failure and 
CD4 trends as well as on mortality after 24 months of ART initiation. Early deaths occurred among 
patients presented late to ART and majority of deaths were attributable to TB. Baseline VL >100,000 
copies/ml was a predictive factor for virologic failure, CD4 changes and mortality. Transmitted drug 
resistance rate should be monitored regularly and prospectively in Vietnam. Using ExaVir Load is 
feasible to monitor efficacy of ART programs in resource-limited settings. 
Keywords: HIV; AIDS; Vietnam; mortality; causes of death; peer support; antiretroviral therapy; 
viral load; ExaVir Load; virologic failure; virologic suppression; limited-resource settings; reverse 
transcriptase; CD4 count; CRF01_AE; transmitted drug resistance; tMRCA.  
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I graduated as a MD from Hanoi Medical University (HMU), Vietnam in 1993 then continued my 
post-graduate training as resident doctor at the National Institute for Clinical Research in Tropical 
Medicine at Bach Mai hospital in Hanoi between 1994 and 1997. After that I obtained my Master’s 
degree and then became a lecturer at the Department of Infectious Diseases of HMU.  
I still remember clearly how I felt when I saw the first case of HIV detected at the hospital in 1995. 
To my knowledge and that of everybody, HIV was considered a deadly contagious disease and the 
associated stigma toward HIV was so severe that HIV became a horrible fear. During the period of 
1995-2000, the HIV epidemic was expanding throughout the country with the number of infected 
cases quickly increased, mainly among young injecting drug users. Every day I despairingly saw 
more and more AIDS patients dying without having medicine, care or treatment combined with high 
levels of stigma from family, community and even health staff. The presence of HIV/AIDS has 
changed the pattern of infectious diseases in Vietnam and it also has changed my life and career 
since then. 
In 2002, I was introduced by professor Le Dang Ha to be involved in a PhD program in the Common 
Diseases Program of HMU in collaboration with Karolinska Institutet (KI), Sweden. However, I had 
to wait until 2004, after completing a one-year fellowship on molecular biology at the Tropical 
Medicine Institute of Nagasaki University in Japan, I first time came to Stockholm and joined the 
HIV group headed by Professor Francesca Chiodi in the Department of Microbiology and Tumor 
Center (MTC) in autumn 2004. 
In 2005-2006, I unfortunately had to put my PhD studies on hold to work for Family Health 
International (FHI) - a Non-Governmental Organization (NGO) in Vietnam. During this time, many 
ART programs supported by PEPFAR and Global Fund had rolled out. As a program officer on 
Treatment and Palliative Care, I started to set up HIV clinics at the district level and the Cam Pha 
and Van Don Districts in Quang Ninh province were chosen because they were HIV “hot spots” 
during that time. I was impressed the first time Dr Rachel Burdon and I conducted a site visit to Van 
Don Islands; we met many HIV widows infected by their husbands who had died of AIDS. I 
understood how much they were suffering. I saw the hope in their eyes when I told them that they 
were innocent, that they should not have been stigmatized, that free ARV drugs were available and 
that by adhering to those treatments they could live longer. We then started to set up a 
comprehensive care and treatment service including Voluntary Counseling and Testing (VCT), 
antiretroviral therapy (ART), palliative care and home-based care for these clinics and soon the 
program became an effective and reputable model for HIV continuum of care at district level in 
Vietnam.   
It was fortunate for me when Associate Professor Ingeborg van der Ploeg (my mentor since 2004) 
re-introduced me to the PhD program as soon as I returned to clinical work in the Infectious Diseases 
Department of Bach Mai hospital in early 2007. I then met Dr. Mattias Larsson and associate 
professor Nguyen Thi Kim Chuc who invited me to join in a randomized controlled trial, 
“DOTARV”, in Quang Ninh where I had previously gained 2 years of experience of working in FHI 
then I could continue my PhD. This was an excellent opportunity for me to return to my PhD and to 
improve my research skills and enhance my clinical knowledge and public health perspectives on 
HIV care and treatment, and ultimately, to prolong and improve the quality of life for patients. In 
May 2007, I became officially registered in the PhD training program at KI under the direct 
supervision of Dr. Mattias Larsson.  
The topic of my PhD program is to investigate the impact of peer support on virologic failure and 
mortality in a cluster randomized controlled trial of 640 patients in Quang Ninh. This was a 
challenge for me as it was the first time I was involved in such a large randomized control trial in a 
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mountainous remote setting. However, for the past 5 years I have worked step by step to improve my 
knowledge and skills. By working with peer supporters, even I do not know for sure if their roles can 
play any significant impact on treatment outcome, but I do believe that what they are doing is very 
important and necessary for the community to reduce stigma and at very least, it is better for the 
patients to gain knowledge and improve their quality of life. We became not only friends, but also 
colleagues so that we could share everything and this helped to propel the project forward. The 
project helped me to open my eyes to see a broader picture of care and treatment in Vietnam and in 
the world to understand about PLHIV, not only as patients in hospital, but also as normal persons 
living in their home and community, in relation to other social activities. 
In November 2009, with support from CDC-Lifegap, an HIV outpatient clinic was opened in my 
Infectious Diseases Department at Bach Mai Hospital and I was appointed as chief of the clinic 
which provides a comprehensive package of care and treatment including inpatient, palliative care 
and ART second-line services. For the past 3years, the number of registered patients has reached 
nearly 1,000. Despite many patients still presenting late with severe immune-suppressed and 
opportunistic infections (OIs), most of them have overcome these and began to thrive after several 
weeks of treatment.  
Today, in the era of highly active antiretroviral therapy (HAART), HIV-infected people can easily 
access ART care and treatment services, thus HIV is no longer considered to be a deadly disease and 
PLHIV can live longer with a good quality of life. However, HIV is a unique and extremely difficult 
disease because it can affect everyone, at every age, with every specialty, and within every 
profession, and is associated with many psychosocial and economic problems. Incredibly, the HIV 
disease progress can now be reversed so that a person dying from HIV-related illnesses can survive 
and live much longer if she/he is fully managed by OIs treatment and adheres to ART. I usually 
bring hope to my patients by telling them that “having HIV is not the end of the world; adhere well 
to treatment and you can live long with a healthy life. Please be optimistic that one day scientists will 
find a cure for AIDS …”     
Recently I saw a photo on the internet of a cemetery of hundreds of graves of young people who had 
died of AIDS and heroin use in Ha Long City. I was touched and sad. Even now HIV epidemic in 
Quang Ninh has been well controlled; we still have a lot of things to do. Anyway, the peace and 
beauty of the World Heritage Site, Ha Long Bay is still attracting tourists from all over the world.  
In December 2008, it was my privilege to attend the Nobel Prize award ceremony in Stockholm, in 
which the Royal Swedish Academy of Sciences awarded laureates Luc Montagnier and Françoise 
Barré-Sinoussi who discovered HIV nearly 30 years ago. In how many years will mankind celebrate 
the day of discovery of a cure for HIV while now every minute 5 persons on earth are infected with 
HIV and everyday 5,000 people die of it? It is still a long journey ahead! 
People usually call me an “HIV doctor”! I do not remember when HIV “stuck” to me. My patients 
usually ask me, “Dr Cuong, you are studying in the West, when you will bring home an AIDS cure 
to help us?” Well, with what I learned from Karolinska Institutet, I still owe a debt of gratitude and 
would like to dedicate and contribute a small work through this thesis to all my beloved patients.  
It is said that “When you finally reach the top of the mountain, the view will be ever so spectacular 
and breathtaking.” The same could be said about the pursuit of a PhD at Karolinska Institutet! How I 
will feel after the 9
th
 day of October, 2012? Thanks everyone for making my dream come true!  
Stockholm, 5
th
 September, 2012 
Đỗ Duy Cường 
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1 BACKGROUND 
1.1  CURRENT HIV EPIDEMIC IN THE WORLD 
1.1.1 Epidemiology 
The human immunodeficiency virus (HIV) is the world’s leading infectious cause of 90% of 
adult deaths in low- and middle-income countries (LMICs) [1]. According to the United 
Nations AIDS Agency (UNAIDS), by the end of 2010, globally estimated 34 million people 
were living with HIV (PLHIV) and 2.7 million were newly infected [1]. Wide access to 
antiretroviral therapy (ART) has improved the prognosis of PLHIV [2,3,4] with 6.6 million 
people having received ART, resulting in substantial declines in the number of AIDS-
related deaths from 2.2 million in 2005 to 1.8 million in 2010 [1,5,6] (Figure 1).   
 
Figure 1: Number of people with access to ART and the number of people dying from AIDS-
related causes in LMICs, 2000-2010 [7]. 
The overall growth of the global AIDS epidemic appears to have stabilized for past few 
years. However, although the number of new infections has been failing, levels of new 
infections overall are still high, and with significant reductions in mortality, the number of 
PLHIV worldwide have increased [6].   
In Africa, Sub-Saharan countries are the most heavily affected by HIV epidemic with an 
estimated 22.9 million PLHA. Some countries with high HIV prevalence are South Africa 
(17.8%), Botswana (24.8%), Lesotho (23.6%) and Swaziland (25.9%). The majority of 
newly infected cases in this region are infected through unprotected heretosexual intercourse 
and onward transmission of HIV to newborns and breastfed babies  [6]. 
In Asia, there are an estimated number of 4.9 million PLHIV in 2009, about the same as five 
years earlier [1].  Most national HIV epidemics appear to have stabilized and no country in 
the region has a generalized epidemic. Prevalence of HIV in Thailand is close to 1%. In 
South and South-East Asia, there are the estimated number of 270 000 PLHIV in 2010. 
Asia’s epidemics remain concentrated largely among people who inject drugs, sex workers 
and their clients, and men who have sex with men (MSM) [1].  
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1.1.2  HIV-1 subtypes 
HIV is divided into two different subtypes: HIV-1 and HIV-2. HIV-1 is divided into three 
major groups: group M (main), group O (outlier) and group N (non-M, non-O) [8]. The 
global epidemic is fueled mainly by group M. Group M has 10 subtypes (A to K). Sub- 
Saharan Africa is predominated by HIV-1 subtype C, which is causing >50% of the global 
HIV-1 epidemic (Figure 2).  
 
Figure 2: Global distribution of HIV-1 subtypes (Source 
http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html) 
The ability of the virus to replicate, known as ‘fitness’ [9], is related to different factors 
depending on its environment, either related to the immune system or drug pressure [10]. In 
vitro data from India show that subtype C is more fit than subtype A [11]. However, 
virologic outcome among subtypes is not a totally understood area [12]. The K103N, M46L, 
I84V, Y181C and Y188C mutations are reported to be more prevalent in subtype C than in 
other subtypes [13,14]. The D30N is reported to be common in subtype B [14]. The most 
common mutation in subtype B was thymidine analogue mutation (TAM) [14]. Subtype B 
is predominant in high-income countries and subtype C is predominant in low- and middle-
income countries; therefore patients might be exposed to different antiretroviral drugs. In 
terms of virologic outcomes, studies from Canada [15], France [16] and the United 
Kingdom [17] found no significant difference between subtype B and other subtypes. 
In Vietnam, the first documented Vietnamese case detected in Ho Chi Minh City was a 
subtype B virus [18], but since then the epidemic has been dominated by the recombinant 
strain CRF01_AE, which is the predominant genotype in South-East Asia [8,19].  
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1.1.3 HIV transmitted drug resistance 
HIV replicates at a very high rate, with billions of copies created on a daily basis. At every 
replication cycle there is the possibility of single mutations, potentially including drug-
resistant variants, due to the high levels of errors associated with reverse transcriptase 
[20,21]. The genetic barrier to drug resistance is defined as the number of mutations 
required to overcome drug pressure and eventually develop drug resistance. Under ARV 
drug pressure, people receiving ART develop resistant strains of HIV named “acquired drug 
resistance” that can be transmitted through exchange of body fluids, and susceptible 
individuals are then infected with the “transmitted drug resistant” (TDR) strains of HIV.  
The emergence and spread of high levels of HIV-1 drug resistance in LMICs where 
combination ART has been scaled up rapidly could compromise the effectiveness of 
national HIV treatment programs because drug resistance to antiretroviral drugs is one of 
the major factors associated with virologic failure [22]. A meta-regression analysis has 
shown a significant increase in prevalence of drug resistance over time since ART roll-out, 
especially in regions of sub-Saharan Africa [23]. 
In high-income countries where ART has been available for a long time, prevalence of both 
acquired drug resistance and TDR was reported high ranged between 35-60% [24,25] and 8-
25% [26,27], respectively. These high levels are largely explained by the long history of 
ART including the early use of suboptimal therapies in these countries. However more 
recent studies show a pronounced decline in acquired drug resistance and also in TDR in 
high-income countries [28,29,30]. According to the World Health Organization (WHO),  
TDR > 5% could be considered as a public health concern [31]. Recent ART roll-outs in 
LMICs utilize more potent regimens with higher resistance thresholds, but the frequent 
absence of viral load (VL) testing and limited availability of second-line ART may result in 
delayed treatment switches, promoting TDRM development despite that the prevalence of 
TDR in these setting remains low [32,33]. Therefore it is recommended that a programmatic 
assessment, informed by surveillance of TDR and acquired HIV drug resistance must be 
regularly performed to timely and adequately adapt policy and implementation practice in 
countries scaling up ART access [1,34]. 
In Vietnam, studies in the North showed that  prevalence of TDR was low ( <5%) [35,36] 
and no increase of TDR prevalence among drug-naïve individuals (from 2.9% in 2007 to 
6.2% in 2008, but only 2.0% in 2009) [36,37]. However, a recent overview study of HIV 
drug resistance in Vietnam has shown that the increasing trend of TDR among recently 
infected-people in urban from was <5% in 2006 to a higher level of 5-15% during 2007-
2008, whereas TDR prevalence among chronic ART-naïve adults was stabilized between 6 
and 8% throughout the country [38]. 
1.1.4 Challenges and strategies to scale up ART programs 
Because HIV/AIDS treatment prolongs life, a continuing rise in the number of PLHIV is 
expected, therefore human and financial resources needed for ART will be much greater. 
Since 2005, vast funding has been allocated for HIV treatment, including ART in low-
income settings through the President’s Emergency Plan for AIDS Relief (PEPFAR), 
Global Fund (GF), and the Bill & Melinda Gates Foundation. Providing ARV drugs to those 
living with both poverty and HIV may not only benefit the individual, but may also be 
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important from a preventive public health perspective. These include: i) a decreased risk of 
HIV transmission as ARV decreases VL to undetectable levels in most patients, ii) earlier 
detection of HIV cases as the availability of ARV encourages voluntary testing for HIV 
infection, iii) improved quality of life, and iv) decreased stigmatization and discrimination 
[39]. However, unless treatment is properly controlled, first-line ARV treatment could 
rapidly become of limited value due to virologic failure and resistance development.  
Despite universal access having made an improvement, only 47% of all people eligible for 
ART are currently on treatment and further scaling-up is needed to provide accessibility to 
ART, especially in sub-Saharan Africa, Eastern Europe, Middle East and parts of Asia[1]. 
There is also an extensive attrition (discontinuation of ART) between HIV testing and 
counseling and care and treatment services. Hence, it is crucial that the current model for 
HIV treatment must evolve if universal access is to be achieved and sustained [1]. 
The WHO set a goal of “Reaching 15 million people with ART by 2015”. The action plan 
includes a scale-up of ART programs by providing ART to PLHIVs with CD4 <350 cells/µl 
as well as HIV-negative partners, pregnant women and high-risk populations, regardless of 
their immune status in order to increase the number of people eligible for treatment in 
LMICs [1,40].  
In 2011, a large multi-country study by the HIV Prevention Trials Network (HPTN 052) 
showed that ARVs cut transmission of HIV by 96% within couples where one partner is 
HIV-positive and the other is not infected [40]. On the basis of this evidence, WHO issues 
new guidelines for treating PLHIV who have uninfected partners ('sero-discordant' couples), 
regardless of the strength of his or her immune system, to reduce the likelihood of HIV 








In response to the vision of “Zero discrimination, Zero new HIV infections, Zero AIDS-
related deaths” by 2015, in July 2011, UNAIDS/WHO proposed the “Treatment 2.0” 
initiative (adopted early by Vietnam, Swaziland, Malawi and China) which aims to 
accelerate progress towards universal ART access. The “Treatment 2.0” will help countries 
to reach and sustain universal access to treatment, and capitalize on the preventive benefit of 
ART through focused work in five priority areas: i) optimize drug regimens; ii) provide 
point of care diagnosis; iii) reduce costs; iv) adapt delivery systems and v) mobilize 
communities [1,41] (Figure 3).     
"Every year, more than a million more people in low- and middle- income 
countries start taking antiretroviral drugs. But for every person who starts 
treatment, another two are newly infected.  Further scale-up and strategic use 
of the medicines could radically change this. We now have evidence that the 
same medicines we use to save lives and keep people healthy can also stop 
people from transmitting the virus and reduce the chance they will pass it to 
another person" - said Dr Margaret Chan, Director-General, WHO. 
The XIX International AIDS Conference, Washington DC, USA, July 2012. 
 17 
  
Figure 3: Priority work areas of “Treatment 2.0” (Source: WHO-2012) 
By implementing “Treatment 2.0”, an additional 10 million deaths could be averted by 2025 
[6]. Treatment can become part of a combination prevention strategy, therefore the new 
HIV infections could be reduced by one-third. A better single-dose pill with low toxicity 
that was resistant-proof would have less for treatment monitoring, thus reducing the costs of 
health-care time for monitoring patients and lowering out-of pockets costs for the patients. 
Late treatment initiation for patients with often severe clinical conditions requires 
significant levels of clinical care. This is avoidable through treatment initiation prior to the 
development of severe HIV-related diseases (Figure 4). In addition, it can improve uptake 
of HIV testing and linkage to care, as well as reduce the associated stigma and 
discrimination. Finally it strengthens community mobilization by improving the ability of 
populations at high risk (IDU, MSM, FSW) to access HIV services. A WHO evaluation of 
186 community-based service delivery projects in Europe, South-East Asia and Latin 
America found that local community-based organizations led by PLHIV are the best places 
to reach populations at higher risk of HIV [1].   
 
Figure 4: Comparison of ART costs per person-year for early and late treatment initiation. 
















1.1.5 Access to VL and drug resistance testing 
To ensure the sustainability of ART programs in resource-limited settings, it is essential to 
find effective ways to maintain patients on first-line regimens as long as possible [5]. VL 
measurement is a gold standard for monitoring the effectiveness of ART programs 
[42,43,44,45,46]. The aim of ART is to suppress viral replication as much as possible 
[5,47]. In high-income countries, the optimal virologic suppression is generally defined as 
a VL persistently below the level of detection (less than 20 to 75 copies/ml, depending on 
the assay used) [48,49,50]. In high-income countries, viremic patients are assessed 
routinely for the presence of drug resistance mutations by using advanced laboratory 
assays [22,51]. However, virologic monitoring is not widely accessible among LMICs due 
to high cost and requirement of an advanced equipped laboratory [42,43]. 
Recently, WHO guidelines encourage LMICs to increase access to VL testing where 
feasible, particularly for clinical decision-making related to switching drug regimens 
[42,52]. According to these guidelines, virologic failure is defined as persistent >5,000 
copies/ml [42]. In the absence of VL testing, the recommendations are to use clinical 
symptoms or CD4 cell count as a proxy for virologic failure [53] with the criteria used to 
define immunologic failure being: (i) a CD4 count <100 cells/µl post-6 months on ART, 
(ii) a reduction to or CD4 count below the pre-ART CD4 count level, post-6 months on 
ART, or (iii) 50% fall from the on-treatment peak CD4 value [42]. However, there is 
growing evidence to show that relying only on CD4 cell count assessment is neither 
sensitive nor specific for virologic failure [44,54,55]. As rapid scaling up of ART 
programs occurs in LMICs, a low-cost diagnostics to sustain use of the first-line regimen 
in LMICs therefore is needed [38,42,56]. 
The ExaVir
TM
 Load assay is an ELISA-based VL method from Cavidi (Uppsala, Sweden). 
It measures the activity of the HIV reverse transcriptase (RT) enzyme which is proportional 
to the number of VL in the plasma [57,58,59]. This is a simple technique that does not 
require an advanced PCR laboratory so it can be performed in decentralized settings in 
LMICs [60,61]. A good correlation between the ExaVir Load and the PCR has been proven 
in several studies [57,59,60,62,63]. However, there are no studies describing the 
implementation of this assay in monitoring a long-term longitudinal study in rural resource-
constrained settings.   
1.1.6 Tuberculosis and HIV 
HIV-related TB remains a serious challenge for the health-sector response and for PLHIV. 
Of the 34 million PLHIV worldwide, about one-third is estimated to have concomitant 
latent infection with TB. PLHIV are about 21–34 times more likely to develop TB, 
compared with those who are HIV-negative [64,65].  In 2010, among 8.8 million TB, 1.1 
million were HIV-infected with an estimated 350,000 associated deaths. HIV is the 
strongest risk factor for developing active TB disease, and in African countries up to 44% of 
people with TB have HIV and about 13% of TB cases occur among PLHIV [65].  
The success of TB/HIV therapy can be jeopardized due to either drug-drug interaction 
and/or the increase in pill burden for patients [66,67]. Collaborative activities between 
national TB and HIV programs are essential to prevent, diagnose and treat TB among 
PLHIV and HIV among people with TB. These include establishing mechanisms for 
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collaboration, such as coordinating bodies, joint planning, surveillance and monitoring and 
evaluation; decreasing the burden of HIV among people with TB (with HIV testing and 
counseling for individuals and couples, co-trimoxazole preventive therapy, ART and HIV 
prevention, care and support); and decreasing the burden of TB among PLHIV (with the 
three I’s for HIV and TB: Intensified case-finding; TB prevention with Isoniazid preventive 
therapy and early access to ART; and Infection control for TB) [65].  
Initiating ART for all PLHIV with CD4 counts <350 cells/µl or with active TB irrespective 
of CD4 count is crucial to prevent TB- and HIV-related transmission, morbidity and 
mortality. Integrating HIV and TB services, when feasible, may be an important approach to 
improve access to services for PLHIV, their partners, families and the community [65]. 
 
1.1.7 HIV mortality and causes of deaths 
After more than 30 years after the start of the HIV epidemic, today approximately 30 
million individuals have died of AIDS. However, AIDS-related mortality worldwide has 
declined since 2005-2006 due to the increased availability of ART [2,3,4], as well as 
improved care and support to PLHIV and the decrease in number of newly HIV-infected 
people, especially in sub-Saharan Africa [1]. Early mortality has remained high after 
initiation of ART due to late presentation with advanced immunodeficiency in LMICs 
[68,69,70].  
The causes of death differ from LMICs to high-income countries [69,71,72] and evidence 
showed that TB is still a leading cause of death among worldwide PLHIV [68]. In addition, 
there is the increased and prominent proportion of deaths that are attributable to non-AIDS 
diseases [73]. Verbal autopsy can be used as a tool for diagnosing HIV-related deaths in 
LMICs [74,75]. 
1.1.8 Adherence to ART and role of peer support 
1.1.8.1  Adherence assessment 
Adherence to ART is critically important for PLHIV as it has a major influence on 
virologic failure and HIV drug resistance development [51,76,77]. However, the biggest 
obstacle for ART adherence is that the PLHIV have to take drugs for the whole of their 
lives. Because adherence assessment can only be ensured by a “directly observed therapy” 
and it is impractical to measure the drug concentrations in the plasma of the patient 
[78,79], there is neither a standard for the assessment of adherence nor a single optimal 
tool that enhances ART [79]. There are several methods to measure barriers to adherence 
to ART, including: i) pharmacy drug-refill appointment (this is one of the early warning 
indicators (EWIs) proposed by WHO in which patients are assessed at refill visits at clinic 
on dispensing day on monthly basis) [31,80,81]; ii) self-report adherence: patients are 
asked about the number of missed doses during the last four days of the last week 
[82,83,84] or by visual analogue scale by using an ordinal scaling system for adherence 
level which is evaluated by showing the percentage of adherence on the scale from 0-
100% [85]; iii) pharmacy pill count [86]; iv) medical electronic monitoring system 
[87,88]; and v) therapeutic drug monitoring of the ARV concentration on blood or hair 
[78,79,89].  
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The main reasons for non-adherence related to patients are simply forgetting; being 
busy/distracted; and being away from home [84]. From health care services, barriers to 
adherence included financial constraints, pharmacy drug stock-out and not understanding 
the treatment. From a systematic review study, the important barriers reported in both 
economic settings included fear of disclosure, concomitant substance abuse, forgetfulness, 
suspicions of treatment, regimens that are too complicated, number of pills required, 
decreased quality of life, work and family responsibilities, falling asleep, and access to 
medication [90]. The important facilitators reported by patients in developed nation settings 
are having a sense of self-worth, seeing positive effects of antiretrovirals, accepting their 
sero-positivity, understanding the need for strict adherence, making use of reminder tools, 
and having a simple regimen [90].   
1.1.8.2  The role of peer support 
The provision of ART in LMICs entails substantial challenges due to shortage of human 
resource [1]. WHO and PEPFAR have advocated a strategy to mobilize the involvement of 
PLHIV through task shifting among health workforce team [91]. The intervention of peer 
support as a part of HIV care and treatment has been used since the beginning of the HIV 
epidemic, and interventions based on peer support have been indicated to be feasible, 
practical, cost-effective and exportable [92]. In sub-Saharan Africa, peer support and home-
based care have become an essential part of the HIV comprehensive care and treatment 
package [39,93,94], in which the role of peer support is acknowledged as an essential 
activity for treatment success [95,96]. Farmer P. et al (2001) showed a good adherence 
using directly observed therapy (DOT) with ART and concluded that it could be delivered 
effectively in low-income settings if there is an uninterrupted supply of high-quality drugs 
[97]. Bartlett J.A. (2002) has also suggested that to increase adherence, it is necessary to 
make an effort to motivate and educate the patient as peer support is a form of social support 
which can affect adherence by the patients [98].  
However, the relationship between the degree of decreased drug sensitivity and resistance, 
and the degree of adherence, for all categories of ARV drugs, has not been studied in 
prospective randomized cohorts, neither in patients given conventional therapy in high-
income countries, nor during DOT in low-income settings. 
A recent cluster randomized controlled trials in Uganda showed that a community-based 
peer health workers intervention only had an effect on reducing virologic failure rate after 
96 weeks of treatment [99]. Another meta-analysis review indicates that peer education 
programs in developing countries are moderately effective at improving behavioral 
outcomes but show no significant impact on biological outcomes [100]. On the other hand, 
in most Asian countries, where the HIV epidemic is in a concentrated stage, in targeting the 
high risk population, such as injecting drug users (IDUs) and sex workers, the adherence 
support may pose different challenges [101], hence the impact of peer support on virologic 
failure in Asian countries has not been assessed.  
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1.2 VIETNAM 
1.2.1 Country context 
Vietnam, situated in Southeast Asia, is bordering China in the north, Laos in the northwest, 
Cambodia in the southwest and with a long coast to the east. Having an area of 
331,210 square kilometers and a population of about 90 million (70% resided in rural areas- 
2010), Vietnam is the world's 13
th
 most populous country.   
Since 1986, when the government’s political and economic reform (“doi moi”) policies 
were launched, Vietnam has been rapidly transformed within a quarter of a century from 
being one of the poorest countries in the world, with per capita income below USD 100, to 
being a lower- middle-income country with per capita income of USD 1,160 by the end of 
2010. The ratio of population in poverty has fallen from 58% in 1993 to 14.5% in 2008, and 
most indicators of welfare have improved (Table 1). Vietnam has already attained five of its 
ten original Millennium Development Goal targets and is well on the way to attaining two 
more by 2015 [102]. 
Table 1: Vietnam demographic health indicators (Source: The World Bank) [102] 
Health indicators 1986 2006 2010 
Population (million) 61 84 88 
GNI per capita (Atlas method) (USD) 220 (1989) 700 1,160 
Birth rate (/1,000 population) 33 17 17 
Death rate (/1,000 population) 9 5 5 












Infant mortality rate (/1,000 live birth) - 21 20 
Under 5 mortality rate (/1,000 live birth) - 27 23 
Maternal mortality rate (/100,000 live birth) 240 (1990) 74 (2005) 59 
HIV adult prevalence (%) 0 0.4 0.4 (2009) 
Incidence of TB (/100,000 population) 204 (1990) 203 199 
 
1.2.2 HIV situation in Vietnam 
1.2.2.1  History and epidemiological context 
Vietnam’s HIV epidemic is considered to be one of the fastest growing in Asia and becomes 
one of the 10 leading causes of mortality in the country [103]. Since the first case was 
detected in 1990, over 50,000 people have died of AIDS and at the end of 2010, there were 
254,000 PLHIV (of these, 5,100 were children). The overall prevalence rate among adults 
aged 15-49 was estimated to be 0.44% in 2010 [104] (Figure 5).  
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Figure 5: Gapminder world chart: Relation between HIV prevalence and income (2009). 
Some provinces have progressed to a generalized epidemic with more than 1% of the adult 
population infected with HIV, such as Quang Ninh, Ho Chi Minh City and Hai Phong 
(UNAIDS, 2006). The epidemic affects mainly young males under 29 years of age (70%) 
and is mainly concentrated among most at risk populations such as IDUs (30%), female sex 
workers (FSWs) (9%) and MSM (2%) [104]. 
HIV transmission in Vietnam has so far largely been driven by IDUs and more recently the 
spread of HIV in Vietnam increasingly appears to occur through sexual transmission [105] 
which suggests that the epidemic may become more difficult to control. It is thus important 
to monitor infection patterns and the prevalence of TDRMs in order to direct diagnostic and 
treatment efforts in an efficient manner to minimize the number of new infections.  
TB/HIV and hepatitis/HIV co-infection are becoming a burden for health care system 
[65,106,107]. HIV prevalence among tested TB cases in Vietnam was 8.3% [65] and TB is 
one of the most common co-infections with a high mortality rate (28-29%) [64,108,109].  
1.2.2.2 Scaling up ART programs in Vietnam 
The socio-economic barriers such as stigma, drug addition, limited support from families 
and communities remain for PLHIV to access ART in Vietnam [110,111]. Many patients 
are diagnosed and initiated on ART late with advanced-AIDS disease and OIs [108,112]. 
However, Vietnam has put great effort and made a considerable progress into the control 
of the HIV epidemic by strengthening the continuum of prevention and care to promote 
retention in HIV services. Since 2005, ART programs have been rapidly scaled up with 
support from PEPFAR and Global Fund with 288 public-sector ART clinics throughout 
the country (14 clinic were at the national/central level, 125 clinics were at the provincial 
levels and 149 were at the district level) [81]. Recently, in April 2012, the Ministry of 
Health (MoH) approved the introduction of “Treatment 2.0” in Dien Bien province and 
Can Tho City.  
Vietnam 
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By the end of 2010, 52,000 PLHIV had accessed ART, an 18-fold increase compared to 
2005. As a consequence, the number of deaths caused by AIDS is in rapid decline [113] 
(Figure 6). The estimated coverage rate of ART was, in 2010, estimated to be 75% of those 
in need of treatment, so there are still approximately 65,500 people in need who have not 
yet accessed ART. The limitations of ART’s accessibility might be due to the constraints of 
ART services which greatly depend on the availability of donor support, limitation of VCT 
availability, high workload for health care sectors, shortage of human resources and stigma 
toward PLHIV.    
.  
 
Figure 6: Number of HIV cases, deaths and the needs of ART in Vietnam [113] 
In 2005, the Vietnam Administration of HIV/AIDS Control (VAAC) under the Minister 
of Health was established to assist the Minister of Health in governance and in organizing 
activities on HIV/AIDS prevention and control nationwide. During this year, the Vietnam 
National Guidelines for HIV/AIDS Diagnosis and Treatment (VGHADT) has issued [114] 
and revised twice in 2009 [115] and 2011 [116]. These are legal documents updated from 
WHO Guidelines to help guide health care providers in how to work in all care and 
treatment activities in Vietnam. In the revised versions, CD4 count threshold eligible for 
ART start has increased from 200 cells/µl in 2005 [114] to 250 cells/µl in 2009 [115] and to 
350 cells/µl (2011) [116]. Also in the revised guidelines (2009), PCR VL testing is indicated 
for assessing patients suspected of failing the first-line regimen besides assessing 
immunologic or clinical treatment failures [115].  
1.2.3 Treatment failure and VL monitoring in Vietnam 
VL monitoring is not routinely performed to assess treatment failure in Vietnam. VL testing 
is a gold standard and only available in big cities such as Ha Noi and Ho Chi Minh City and 
is used mainly for accessing treatment failure and in making decisions for switching to 
second line treatment [117,118]. 
According to VGHADT, treatment failure is defined if patients have been on 3-drug ART 
for at least 6 months and are compliant with treatment. Criteria for i) clinical failure are: 

























therapy; ii) immunologic failure: if CD4 count returns to or falls below pre-therapy 
baseline level or 50% decline from the on-treatment peak value since the initiation of 
ART (if known), or CD4 count <100 cells/µl after a year without any increase; and iii) 
virologic failure: if plasma VL > 5,000 copies/ml [115]. 
The Vietnam MoH is currently issuing “the Guidelines on VL monitoring for HIV patients”, 
in which VL can soon be routinely performed with yearly basis for every patient receiving 
ART after 6 months.   
1.2.4 Quang Ninh province 
1.2.4.1 HIV situation in Quang Ninh 
Quang Ninh province is located along the northeastern coast of Vietnam with a population 
of 1.1 million and and area of 6,100 square kilometers. It has 14 cities/districts, of which Ha 
Long City is the biggest (20 communes, 221,000 habitants) with the famous World Heritage 
Site, Ha Long Bay. Coal mining, fisheries, and tourism are the main industries.  
HIV prevalence in Quang Ninh was considered highest in Vietnam, about 1% of the 
population (11,246 PLHIV and 1,100 AIDS-related deaths and 800 non-AIDS related 
deaths - reported in 2006); 55% of PLHIV were IDU, and the prevalence of FSW infected 
with HIV was increasing from 0.44% in 1988 to 2.5% in 2005- reported by Provincial AIDS 
Committee). By November 2006, only 720 people in the province had been receiving ART 
supported by the National programs.  
Care and treatment programs have been introduced in Quang Ninh province since 2005 with 
support by PEPFAR (Ha Long City) and Global Fund (Uong Bi City, Dong Trieu and Yen 
Hung districts) and the number of patients who access to ART in the region has been 
increasing. Many community-based activities have been set up to provide support for 
PLHIVs under NGO organizations such as home-based care by Family Health International 
(FHI), IDU support group by CARE International, Community Health and Development 
(COHED) and other self-care groups such as the “Bright Futures”, “Shared-Feelings”, 
“Women’s Union”, “Cactus Flower”, “Orphan and Vulnerable Children (OVC)”, “Sun 
Flower” and others. Peer support groups have been assumed to reduce the stigma and 
discrimination, improve the voluntary Counseling and Testing (VCT), enhance adherence 
support and refer of patients to ART clinics.    
1.2.4.2 Role of peer support in Quang Ninh 
In Vietnam, evidence shows that the community-based peer support had an impact on the 
reducing of stigma and discrimination, increasing access to counseling and testing, 
improving quality of life and enhancing adherence to ART. In a qualitative study conducted 
among 48 PLHIV about adherence obstacles encountered during ART, methods that 
patients used to enhance adherence, treatment support structures, and attitudes toward home 
delivery of ART showed that stigma was identified as a strong barrier to ART adherence 
and that patients wished more community-based support, preferably from PLHIV who had 
received sufficient training [110,119]. 
Recent studies in Quang Ninh have shown that home delivery of ART medications was seen 
as undesirable by PLHIV, who feared that it might increase stigma and discrimination. 
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Instead, they wished to have a more community-based support, preferably from PLHIV who 
received sufficient training [110]. In addition, peer support improved quality of life after 12 
months among ART patients presenting at clinical stages 3 and 4 at baseline, but had no 
impact on quality of life among ART patients enrolled at clinical stages 1 and 2 [119]. 
However, the impact of peer support on treatment outcomes, especially on the virologic 
failure has not yet been known as routine VL is not recommended as a routine strategy in 
the national guidelines. 
1.3 RATIONAL FOR THE STUDY 
We conducted this study with the aim of testing the hypothesis that enhanced adherence 
intervention by peer support has an impact on virologic and immunologic responses and 
mortality in HIV-infected patients initiated on the first-line ART regimens in a rural 
resource-limited setting in Quang Ninh, Vietnam. ELISA-based ExaVir Load test was used 
to monitor routinely the VL every 6 months. This approach will provide evidence-based 
ART strategies in large populations in low- income- and low- prevalence settings that may 
have an impact on treatment guidelines for HIV globally. The primary outcome is to assess 
the rate of virologic failure; the secondary outcome is to assess the time to develop virologic 
failure, CD4 trends and mortality.  
Research question: 
Does enhanced adherence by peer support have any impact on the ART 





2 GENERAL AND SPECIFIC OBJECTIVES 
2.1 GENERAL OBJECTIVE 
To assess the impact of peer support on virologic, immunologic outcomes and 
mortality rate among HIV-infected patients receiving ART in Quang Ninh province, 
Northeastern Vietnam. 
2.2 SPECIFIC OBJECTIVES: 
1) To assess the prevalence of TDRMs ART-naïve patients in Northern Vietnam and to 
perform phylogenetic analyses including molecular clock calculations to investigate 
the HIV transmission patterns in this area (I).  
2) To assess mortality rate, causes of death, risk factors and impact of enhanced 
adherence by peer support on survival among a cohort of treatment-naïve HIV-
infected patients initiating the first-line ART regimens (II). 
3) To assess the ART efficacy by ExaVir Load monitoring, compared with PCR 
TaqMan (III).  
4) To compare the virologic failure rates, time to failure and CD4 trends between 
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3.1  STUDY SETTING 
The cluster randomized controlled trial “Directly Observed Therapy for Antiretrovirals” 
(DOTARV), registration number NCT01433601, was carried out within 4 districts/cities: 
Ha Long, Uong Bi, Dong Trieu, Yen Hung including a total of 71 communes (28 urban and 
43 rural) in Quang Ninh province (Figure 8). Reasons for choosing these 4 districts/cities 
were: (i) lack of community-based care, (ii) adjacent areas, and (iii) high HIV prevalence. 
The aim was to use the peer supporters to assess their impact on virologic failure in a cluster 
randomized controlled trial. To minimize selection bias and contamination, the unit of 
randomization and analysis was the cluster (commune).  
Patients were recruited from four outpatient clinics (OPC) including: Ha Long CDC-
LifeGap clinic, located in the provincial hospital in Ha Long City and supported by 
PEPFAR which has more resources, and three Global Fund supported clinics (Uong Bi, Ha 
Long Health Center and Yen Hung).  
 
 
Figure 8: Map of Vietnam and four study sites in Quang Ninh province 
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3.2  RECRUITMENT AND STUDY PROCEDURES 
This trial was conducted between July 2007 through November 2011, with two years of 
patient recruitment and two years of follow-up.  
According to the VGHADT (2005) [114], HIV-infected individuals are eligible to be 
registered for free at an ART clinic if  they: i) are confirmed HIV-positive, ii) possess civil 
registration (home address and telephone); iii) have a family member who can act as an 
internal supporter, and  iv) agree to enroll and to be followed up in the ART program.  
Each district clinic is usually structured by the following staff: two treating doctors, one 
adherence counselor, one reception nurse, one phlebotomy nurse, one pharmacist and one 
volunteer who is a PLHIV. The staff receive a monthly salary or allowance and are trained 
on basic and advanced HIV care and treatment (module 1 and module 2) and certified by 
experts of MoH and Harvard Medical School AIDS Initiative in Vietnam (HAIVN) [120].  
All registered patients receive a set standard of care and are assessed for socio-economic 
situation; and by clinical examination, including the WHO clinical stage, TB and OI 
screening, and testing for viral hepatitis B, C and CD4 count and receiving co-trimoxazole 
prophylaxis. Those who are eligible for ART (clinical stage 4 or CD4 <200 cells/µl or 
clinical stage 3 with CD4 <350 cells/µl) are put on a waiting list for ART with the rule “first 
come, first served”. Patients diagnosed with OIs are treated by OI medications. If TB is 
diagnosed, patients are referred to the provincial TB hospital (named “K67 hospital” and 
located in Ha Long City) and they are initiated with ART after receiving two months of 
intensive TB treatment. Every month, a range of 15-20 patients per clinic are selected to 
attend pre-ART readiness training on both individual and group basis. Training includes 
HIV basics, stigma and discrimination, positive living, transmission prevention, ARV 
regimens and ADRs, and treatment adherence. A family member also attends the training 
and becomes an adherence supporter for the patient. ARV drugs are provided in pre-packed 
dosage form for easy reminding and counting of the pills. The first-line ART regimens 
include: two nucleoside reverse transcriptase inhibitors (NRTIs): stavudine (d4T) or 
zidovudine (AZT) or plus lamivudine (3TC), combined with one non-nucleoside reverse 
transcriptase inhibitor NNRTI: nevirapine (NVP) or efavirenz (EFV). All care and 
medications were provided free of charge. 
Patients who participated in the DOTARV study were selected from the pre-ART waiting 
list. The patients were informed about the trial by study doctors, and then, if they agreed to 
participate, they signed an informed consent form. Study doctors would assign patients to 
either intervention group or the control group based on the commune where they were living 
from one of a total of 71 communes (clusters) in 4 districts. The ratio intervention: control 
communes was 36:35 (1:1). The clusters were randomized by a statistician who was non-
relevant to the study and followed the criteria (i) urban vs rural, (ii) vicinity, and (iii) 
population. The patients in the intervention group received peer support and measured VL 
every 6 months. This study followed an open label cluster randomized controlled trial 
design.  
Inclusion criteria for study participants (i) confirmed HIV-infected, (ii) reported as ART-
naïve, (iii) resident in any of the four study districts, (iv) age 18 years or older, (v) eligible 
for ART according to the National Guidelines (2005), CD4 count <200 cells/µl or clinical 
 29 
stage 4, or clinical stage 3 with CD4 count <350 cells/µl, (vi) willing to be followed up and 
to receive adherence support by a peer supporter, and (vii) having signed a written informed 
consent. Exclusion criteria were (i) pregnancy or (ii) mental illness (Figure 9). 
 
 
Figure 9: Study design 
3.3 INTERVENTION STRATEGY: PEER SUPPORT 
The peer support intervention strategy was home-based adherence counseling conducted by 
peer supporters who were HIV-infected individuals on ART as nominated by fellow 
patients at each clinic site along with the health care staff. The qualifications needed for peer 
supporters were (i) social ability, (ii) good ART adherence for at least six months, (iii) high 
school graduation, (iv) willingness to participate in the study, and (v) passed the qualifying 
test after the training. The proportion of the peer supporters to the number of recruited 
patients living in each district was about 1:20, meaning that one supporter would support a 
maximum of 20 patients. The peer supporters received one-week’s training on basic HIV 
care and support, communication and counseling skills and on filling out the adherence 
checklist form [Appendix 1]. Training curriculum was based on the Family Health 
International (FHI) home-based care booklet (2005) and the training sessions were 
conducted by project researchers. Two one-week refresher trainings sessions were provided 
yearly throughout the study.  
The standard support performed by peer supporters included home-based visits and 
completion of the adherence checklist form in which patients were asked about their well-
being, OI and ADR signs and symptoms, time-points to take pills, any doses missed over 
the last four days, barriers to adherence and pill count. If an incomplete adherence was 
reported, the peer supporter would counsel and discuss with the patients and family 
supporters how to improve the adherence. 
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The initial schedule of support was twice a week in the first two months, and then reduced 
to once a week when patients’ adherence was assessed as good. Additional visits were 
provided if patients were sick or had serious adverse drug reactions (ADRs) or a history 
poor adherence. A telephone call or appointment place could be arranged in advance 
between peer supporters and patients to minimize wasting time or to ensure confidentiality 
for patients who feared disclosure of their HIV status to others in their surroundings. Due to 
the associated stigma, the peer supporters did not wear a work outfit for home visits to 
minimize the patient’s fear of stigma developing from others in their surroundings. Twice a 
month, supervision of peer support activities in each district was reviewed by a peer support 
group leader in each district. Monthly supervision meetings of peer support activities were 
performed by the project researchers. 
Patients in both intervention and control groups received a set standard of care and 
treatment according to VGHADT (2005) [114] including three pre-ART initiation and 
adherence training sessions on both an individual and group basis. Health checks, blood 
sampling and drug dispensations were carried out on a monthly basis at the OPC. Self-
reported adherence for the last four-day period was assessed quarterly by an adherence 
counseling staff member. CD4 counts were run at baseline and every six months using the 
Partec CyFlow
®
 system in Uong Bi General Hospital and the Becton Dickinson
®
 system in 
Quang Ninh provincial hospital. 
3.4 VIRAL LOAD (EXAVIR LOAD) MONITORING 
 This study marked the first time that the ExaVir Load was used in Vietnam to monitor ART 
outcomes in PLHIV. The ExaVir Load was chosen due to the following reasons: (i) simple 
assay in procedure and equipment suitable for using in rural areas, (ii) low cost tests, and 
(iii) the detection limits range between 200 to 410,000 copies/ml (Figure 10). 
 
Figure 10: Start-up equipment for ExaVir Load (Source: http://www.cavidi.se)  
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The implementation plan of ExaVir Load assay in Uong Bi General Hospital was executed 
as follows: two technicians from the Heamatology Department the hospital attended two on-
site training sessions conducted and certified by Cavidi experts (one in July, 2007 and one 
refresher training session in March, 2010). Five-ml blood samples with Ethylene diamine 
tetra acetic acid (EDTA) anticoagulant were collected before initiation of ART and every 6 
months thereafter on the drug dispensing days at the clinics and were then transported to the 
Hematology Laboratory Department in Uong Bi General Hospital (blood samples of 
patients from Uong Bi, Yen Hung and Dong Trieu were taken directly at Uong Bi OPC, 
however blood samples taken in Ha Long were transferred within about one hour and half 
by motorbike to Uong Bi). The blood samples were then centrifuged to extract plasma and 




C if they were to be kept for more than 6 months). On average, 
60 samples (2 runs) were analyzed every month and the results of the VL tests were 
reported to treating doctors, study researchers and adherence counselors. All of the ExaVir 
kits, consumables and start-up equipment were shipped from Cavidi AB, Uppsala, Sweden 
and results were sent to Cavidi specialists for quality assurance.  
 
ExaVir Load testing in Uong Bi General Hospital 
3.5 ADHERENCE ASSSESSMENT 
In both the intervention and control groups, patients were assessed by health care staff at the 
clinic for adherence every 3 months using an adherence checklist modified from the 
contextualized Adult AIDS Clinical Trials Group (AACTG) adherence instrument [84]; in 
which patients reported if they had had any OI or ADR symptoms or if they had missed any 
doses during the last 4 days and if they had correctly measured their pill-count. 
Incomplete adherence was defined as if a patient stated in the 3-month adherence checklist 
form that he or she missed more than one dose (2 or more) either morning or evening of 
ARV during the 24 months of their follow-up time.  
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Complete adherence was defined if a patient stated in the 3-month adherence checklist form 
that he or she did not miss any dose or just one dose (either in the morning or evening) of 
ARV drugs during the 24 months of their follow-up time.  
In the intervention group, peer supporters filled in the one-page adherence checklist form, 
developed by project researchers, in which patients reported about OI and ADR symptoms, 
time at which the pills are taken, number of doses missed for the last 4 days, reasons for 
missing doses, and pill-count. If an incomplete adherence was reported, the peer supporter 
would counsel and discuss with the patients and family supporters how to improve the 
adherence.  
3.6 DEFINITIONS 
Virologic suppression was defined when the patients had VL undetectable (<200 copies/ml) 
at months 6; 12; 18; 24.  
Virologic failure was defined as either (i) primary virologic failure if VL >1,000 copies/ml 
after 6 months of ART initiation, or (ii) secondary virologic failure if VL was undetectable 
(<200 copies/ml) after 6 months of ART initiation and then became >1,000 copies/ml at any 
time point during the follow-up. Patients with virologic failure were reported to the 
attending medical doctors and adherence counselors in their respective clinics. Then a 
follow-up VL testing was repeated after at least one month but within 3 months of the initial 
virologic failure. If VL was still >1,000 copies/ml, the patient was then reported to an OPC 
doctor and flagged for a confirmatory PCR VL. According to VGHADT (2009) [115], 
patients are eligible for switching to second-line therapy if they meet the criteria of clinical 
or immunologic failure and, if available, they have been confirmed to have a PCR VL 
>5,000 copies/ml. Additionally, patients with detectable viral load in the intervention group 
received an intensive adherence counseling support by the peer supporters through the 
provision of two-to-three home visits per week. 
“Blips” were defined as intermittent episodes of detectable low-level viraemia (200 – 1,000 
copies/ml) which return spontaneously to an undetectable range without any change in 
therapy.  
Death events were ascertained by a medical doctor confirmation or, in the intervention 
group, by a peer supporter through telephone calls or home visits. In cases of a missing 
follow-up, event of death was confirmed through telephone calls to family members and 
home visits by peer supporters.     
Lost-to-follow-up was defined as: when the patient was either arrested or placed in a 
compulsory drug rehabilitation center for 24 months due to active heroin use, thus disabling 
follow-up during the study period; or when the patient did not show up at the OPC for 3 
consecutive visits; or if the patient voluntarily withdrew from the study.  
Transferred patients were defined as those who were confirmed as being registered with 
another OPC which was outside of our four study sites. 
Changed-regimen was defined as a patient who had to change one of the three ARV drugs 
in the regimen for any reason (adverse drug events or TB co-infection treatment) during 
ART.   
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Causes of death were confirmed by reviewing medical records and interviews with 
patient’s relatives using a verbal autopsy questionnaire as well as through the meetings 
between researchers and treating doctors to identify the likely causes of death. The verbal 
autopsy questionnaire was adapted from a WHO tool (the International Standard Verbal 
Autopsy Questionnaire) [121] and revised by the researchers to be adapted to deaths related 
to HIV. Interviews for verbal autopsies were conducted as home visits arranged between 
interviewers (researchers) and family members who cared for and supported patients while 
they were dying. Verbal consent was obtained from the family before conducting the 
interview.  Based on the reported symptoms of the patients before they died, combined with 
the information in the patient records and the report from the treating physician, a likely 
cause of death was assigned. 
3.7 STUDY ENDPOINTS 
The primary endpoint was a virologic failure rate between the two groups after 24 months 
of follow-up. The secondary endpoints were to compare between the two groups the 
measures of time to virologic failure, virologic suppression rate, and CD4 changes after 24 
months of follow-up (IV). We also looked at other endpoints: risk factors for virologic 
failure (III, IV), CD4 changes and deaths (II), retention in care rates (II, III, IV), mortality 
and causes of death (II, IV), and rate of TDRMs (I).    
3.8 DATA COLLECTION 
Data were archived in the project office based in Uong Bi town where two staff members 
were responsible for entering these into the database. Data were collected as follows: i) 
baseline socio-economical assessment (I-IV), ii) clinical data (including CD4 and VL) for 
the first visit and follow-up visits every 3 months (I-IV), iii) ART adherence forms 
completed by peer supporters [Appendix 1] (IV); (iv) self-reported adherence forms 
completed every 3 months by health care staff [Appendix 2] (IV); and v) verbal autopsy 
questionnaires [Appendix 3] were collected in between 1-3 months after deaths were 
confirmed. Patient outcomes (deaths, treatment failures, transfers, or lost-to-follow-up) were 
updated monthly through supervision meetings coordinated by researchers. VL data were 
collected by a researcher and entered in the ACCESS file and updated at each monthly 
meeting. Supervision visits and a cross-check approach were used to ensure the quality of 
data. 
3.9 STATISTICAL ANALYSIS 
3.9.1 Sample size (II, IV) 
Patients were allocated to the intervention group according to a randomization of clusters 
(communes) where patients lived. Assuming the difference between the two study arms for 
virologic failure was 15%, the corresponding baseline figure for virologic failure rate was 
20%; had a power of 80% and the significance level of the two-sided alpha was 0.05. The 
total number of clusters was 71. The average number of patients per cluster was 9. A 
randomization ratio of 1 (intervention):1 (control) was assumed. Cluster sample size 
calculation based on Kish’s correction [122] was calculated. The estimation of intraclass 
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correlation coefficient was 0.1. Adding 30% for lost-to-follow-up rate, the total of sample 
size was 629 patients (about 315 patients per study arm). 
The assumptions about differences are based on the following: i) Differences larger than 
10% units in virologic failure are indications for review and modification of treatment 
strategies, and ii) group differences in virologic failure less the 20% are unlikely to lead to 
policy changes in Vietnam.  
3.9.2 Specific analytical methods (I) 
3.9.2.1 Study population 
Baseline samples were collected at the time of ART initiation from 63 ART-treatment naïve 
patients from 640 patients in the cohort between December 2008 and January 2009. 
Samples were stored in -80
o
C freezer in Uong Bi General Hospital and then transported to 
the Department of Laboratory Medicine, Karolinska Institutet Huddinge, Stockholm, 
Sweden, in May, 2009.  
3.9.2.2 Amplification and sequencing 
Viral RNA was isolated from 1 ml plasma, which was concentrated through high-speed 
centrifugation (20,000 g for 80 min at 4
o
C) and 140 µl was used for RNA extraction using 
QIAamp ViralRNA kit (QIAgen GmbH, Hilden, Germany) according to the manufacturer’s 
instructions. cDNA was synthesized using SuperScript III First-Strand Synthesis Supermix 
(Invitrogen, Carlsbad, CA, USA) with random hexamer primers and a product spanning 
protease and the first two-thirds of reverse transcriptase gene of the HIV-1 pol-gene (ref 
HXB2: 2135-3338) was amplified using the primers JA204F-AE (5’- 
CTCAGAGCAGACCAGAGCCAACAG-3’) and JA205R-AE  (5’- 
TTTTCCCACTAATTTCTGTATATC-3’). PCR-products were purified using the 
QIAquick PCR-purification kit (QIAgen GmbH, Hilden, Germany) and sent to Eurofins 
MWG Operon in Ebersberg, Germany for sequencing with the PCR-primers  JA204F-AE 
and  JA205R-AE and plus an additional primer, SeqR-AE (5’-
TACATACAAGTCATCCATGTATTG-3’). 
3.9.2.2.1 For studying the transmitted drug resistance at baseline 
Sixty-three pol-gene sequences obtained from ART-naïve Vietnamese HIV-patients were 
aligned and edited using the BioEdit and ReCall software[123] and a consensus sequence 
spanning 1000 bp was created for each sample, covering codons 1-99 for the protease gene 
and 1-234 for the reverse transcriptase gene. Secondary peaks were called automatically in 
ReCall if they reached ≥20% of the primary peak, but visual inspection of chromatograms 
was also completed and minor manual adjustments were made. All sequences are available 
in GenBank (accession no HQ852853-HQ852915). Genotypic resistance analyses of all 
sequences were performed using the Stanford HIVdb Sequence Analysis, [124], and 
detected resistance mutations were compared against the TDRM surveillance list [125] as 
well as the IAS-USA 2010 update [126]. Subtype classification was completed using the 
REGA HIV Subtyping tool [127]. 
3.9.2.2.2 For studying the phylogenetic analysis 
In addition to the 63 Vietnamese sequences obtained in the current study, a total of 194 
reference sequences were included in the phylogenetic analysis. All full-length CRF01_AE 
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strains available in the Los Alamos database were used (n=71). Sixty-nine CRF01_AE 
sequences were retrieved from patients included in the national Swedish database InfCare 
HIV, where the first available sequence from each patient was used. No more than two 
sequences from the same country and sampling year were included. In addition, 50 
sequences were retrieved from GenBank on the basis of high BLAST similarity to the 
Vietnamese samples. Finally, four subtype B reference strains from Los Alamos were 
included as an out-group.  
Alignments were made using ClustalX2 [128] and phylogenetic analyses were performed in 
BEAST v1.6.1 [129]. The GTR substitution model with inverse gamma distribution (4 
categories), empirical base frequencies and three codon partitions were used in all BEAST 
runs. Three molecular clock models (‘Strict’, ‘Relaxed: exponential’ and ‘Relaxed: log-
normal’) were tested in combination with five different coalescent tree priors (‘Constant 
Size’, ‘Exponential Growth’, ‘Logistic Growth’, ‘Bayesian Skyline’ and ‘GMRF Bayesian 
Skyride’), resulting in a total of 15 parallel analyses. Each analysis was run for 30 million 
generations and sampled every 3,000th generation. Log-files were analyzed in Tracer 
v.1.6.1  [129], where Bayes Factor calculations were performed to determine which model 
was most appropriate for the data. The best model, using the Relaxed: log-normal clock 
with Logistic growth tree prior (‘ln_log’), was significantly better compared to most other 
models (Bayes factor range 17.5-300.2). However, the difference to the model using 
Relaxed: log-normal clock with Exponential growth tree prior (‘ln_exp’) was less 
pronounced at 8.2. These two models were therefore used for further analyses where each 
model was run in triplicate, using one UPGMA generated and two different random starting 
trees, for 100 million generations each, sampled every 10 000 generations. These six runs 
showed comparable performances (Bayes factor range 0.985-4.184), with the highest 
likelihood for the ‘ln_exp’ run with random starting tree 2. The 10 000 sampled trees from 
this run were annotated using TreeAnnotator v1.6.1 and visualized in FigTree v.1.3.1 
(http://tree.bio.ed.ac.uk/software/figtree/). Sampling dates for all included samples were 
used to calibrate the molecular clock and a previous estimate of tMRCA in the year 1975.5 
for CRF01_AE[130] was used as a prior for the CRF01_AE taxon, which contained all but 
the four subtype B sequences (the prior was set to Normal distribution, 35.5 ± 2 years since 
the last year of sampling, 2009).  
3.9.3 Specific analytical method (II) 
Due to a high level of mortality recorded directly after ART initiation, we decided to assess 
the causes of deaths. Data were collected between 1
st
 July, 2007 and 31
st
 March, 2010 
among 640 patients in the cohort. Verbal autopsies were performed through interviews with 
the patient’s relatives using a verbal autopsy questionnaire. A total of 55/60 (92%) verbal 
autopsies were conducted; 3 cases had moved to other provinces and could not be assessed 
by telephone, and in 2 cases the family members refused to take part in the questionnaire. 
An intention-to-treat approach was used for analyses. The survival time was calculated as 
the period of time from the first day the patient received ART to the date of death, which 
was reported by family members, or medical staff or peer supporters. Baseline socio-
demographic, clinical and laboratory variables were compared by Chi-square tests. Data 
were censored at the date of death or at the last visit to the clinic (medical examination, 
 36 
biological assessment, ART dispensation). Kaplan-Meier curves were used to describe the 
survival trends. The Cox proportional hazard model was used to identify risk factors for 
AIDS-related deaths. Univariate analysis was performed to identify significant variables and 
then multivariate analysis followed to identify the final model that comprises risk factors for 
AIDS-related deaths. All tests were two-tailed and were considered statistically significant 
at p <0.05. The statistical analyses were performed using SPSS version 13.0 (SPSS Inc).  
3.9.4 Specific analytical method (III) 
The aim of this paper was to look at the feasibility of ExaVir Load in monitoring virologic 
outcome and assess its validity in a rural setting in Vietnam and to compare between ExaVir 
Load and PCR TaqMan viral load.  
3.9.4.1 For the patient cohort: 
We excluded 35 (6%) patients who were non-naïve among 640 patients in the cohort. So, 
605 ART-naïve patients were selected to take part in this study.  
Statistical analyses 
Intention-to-treat analysis was applied to estimate treatment outcomes (deaths, virologic 
suppression rate, and virologic failure rate). Survival analysis was used to study the time 
from the start of ART to “virologic failure”. Kaplan-Meier estimations of the survival curve 
and Log-rank test are presented, stratified by baseline VL. A bivariate and multivariate 
flexible parametric survival model [131,132] was used to calculate adjusted hazard ratio as 
well as 95% confident intervals (CIs). Several variables were examined to identify 
prognostic factors. Schoenfeld residuals were used for checking the proportional hazard 
assumptions, no time-dependent variables were considered. P-values <0.05 were considered 
significant in the final model. No interactions were used in the final model. The analysis 
was repeated with a bivariate and multivariate Cox Proportional Hazard model and the 
results were almost the same. The statistical analyses were performed using STATA version 
12.0. (College Station, StataCorp LP, TX, USA).   
3.9.4.2 Quantification of HIV by ExaVir Load 
One-ml patient plasma was thawed and analyzed for HIV RT activity by the ExaVir Load 
assay, according to the manufacturer’s instructions [58]. The procedure consists of two main 
parts: the “separation” for viral reverse transcriptase (RT) isolation, and the “reverse 
transcription”. The plasma is treated to inactivate cellular enzymes and the virus particles 
are then separated from the plasma by the use of a gel that binds the virions. Disturbing 
factors, such as antibodies or antiretroviral drugs are washed away. The virions are lysed to 
obtain the RT. The lysates are analyzed using enzyme linked immune-sorbent assay 
(ELISA) in a 96-well RT reaction plate where RNA templates are bound and DNA 
synthesis induced. The lysates and a reaction mixture with primer and an RT substrate 
(BrdUTP) are added into the wells. DNA synthesis is proportionate to the amount of RT 
enzyme. The DNA product is detected by an alkaline phosphate (mAb-AP) conjugated to 
antibody (α-BrdU) and thereafter a colorimetric AP substrate (pNPP) is added to quantify 
the product. The reaction plate is read at three occasions by a standard plate reader (Sanofi 
Diagnostics, France) at the wavelength 405 nm. The first reading is the zero reading at 10 
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minutes, the second at 2 to 3 hours, and the third on the following day (16 to 24 hours) to 
ensure that small amounts of RT enzyme can be detected (Figure 11 a, b, c).  
The ExaVir Load Analyzer software version 3.0 automatically converts the amount of RT in 
femtograms per millilitre (fg/ml) plasma to the equivalent RNA copies per millilitre of 
plasma (copies/ml). The analytical sensitivity is 1 fg/ml. The measuring range is dependent 
on the duration of the RT assay and the performance of the plate reader used, but, in this 
study, was typically 1 to 3,000 fg/ml, an equivalence of 200 to 410,000 copies/ml (Figure 
12). 
 
Figure 11a: Separation of reverse transcriptase. 
 




Figure 11c: Extraction and quantification of reverse transcriptase by ELISA 
 
 
Figure 12: ExaVir Load result report form 
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3.9.4.3 Quantification of HIV RNA by PCR 
HIV RNA testing was performed by Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 PCR 
VL, version 2.0 (detection limit <40 copies/ml) at the Bach Mai Hospital in Hanoi 
according to the manufacturer’s instructions [8].  
Sixty plasma samples (1 ml each) from 60 patients were randomly selected for a 
comparative study (44 samples from baseline, 16 samples from during ART) and frozen at - 
20
o
C. These samples were then analyzed using both ExaVir Load and Roche Cobas 
AmpliPrep/Cobas TaqMan HIV-1 PCR VL, version 2.0. 
A Spearman’s rank correlation coefficient (r2), along with 95% CIs was calculated for the 
correlation between HIV RT activity and HIV RNA. In addition, we used a Bland-Atman 
plot to calculate the agreement of these two assays.    
3.9.5 Specific analytical methods (IV)  
Intention-to-treat analysis was used to calculate virologic failure rate and a 95% confidence 
interval was stratified by both the intervention and control groups at 6, 12, 18 and 24 
months. Relative risks (RR) were calculated over time, to assess the relationship between 
virologic failure and intervention/control groups. Chi-square tests were performed to 
compare intervention and control groups for demographic and clinical characteristics at 
baseline and virologic failures over time.  
Kaplan-Meier survival curves were produced together with a log-rank test, to estimate and 
test how much the time to virologic failure depends on peer support. Cox proportional 
hazards frailty model, adjusting for potential confounders, was used to analyze the hazard 
rate among the intervention and control groups, taking into account the clustered nature of 
the data. Schoenfeld residuals were used for checking the proportional hazard assumptions; 
no time-dependent variables were considered. The final model was selected using a 
forward-stepwise selection with a p-value cut-off for entering the model equal to 0.1. A 
likelihood-ratio test was used for testing the null hypothesis of no variance of the frailty 
effects. CD4 count trends over time were analyzed using a mixed-effects model with a 
polynomial function of time in the fixed component. Due to the hierarchical structure of the 
data, random effects of clusters, both individuals and measurements, were incorporated into 
the model. Square-root transformation was used for CD4 count approximating a normal 
distribution [133].  
The models were adjusted for the following variables: randomized groups (control vs 
intervention);  age ( >35 years vs <35 years); gender (male vs female); WHO clinical stage 
(stage 1 and 2 vs stage 3 and 4); baseline VL ( >100,000 copies/ml vs <100,000 copies/ml); 
baseline CD4 counts ( >100 cells/µl vs <100 cells/µl); ART-naïve status (yes vs no); history 
of IDU (yes vs no); TB history (yes vs no); history of OIs (yes vs no); having an HIV-
infected family member (yes vs no); receiving ART in Halong CDC clinic (yes vs no); and 
changed ART regimen (yes vs no); and incomplete adherence (yes vs no).   
The above mentioned demographic and clinical characteristics at baseline were tested as 
independent variables, both in the survival and mixed effects models. The p-values less than 
0.05 were considered significant in the final model. The statistical analyses were performed 
using STATA version 12.0 (College Station, StataCorp LP, TX, USA).   
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4 ETHICAL CONSIDERATION 
All four studies were approved by the Hanoi Medical University Review Board (HMURB) 
No 26/IRB and 59/HMURB; No 59/HMURB and 98/HMURB (extension) of Hanoi 
Medical University (Vietnam) and ethical permits No 2006/1367-31/4 from Karolinska 
Institutet (Sweden).  
Before conducting the study, written informed consent was obtained and identifying 
information (names, initials, etc.) were then omitted to ensure confidentiality for every 
patient. Patients in the intervention group were informed about the study and that they 
would be visited by a peer supporter at their house and that this home visit activity might 
disclose the HIV status of patients. When visiting patients’ homes, peer supporters did not 
have to wear work outfits in order to minimize the patient’s fear of being stigmatized from 
others in their surroundings.  
Patients signed the informed consent form and were informed that they had the right to 
withdraw from the study at any time. Biological samples were collected and used only after 
written consent. All blood samples were coded to protect the identity of patients and to 
ensure confidentiality. Patients were recruited in a consecutive manner. No patient 
identifying information was published or made available after the requisite clinical data 
have been collected. Patients in both the intervention and control groups would receive 
equal care and treatment. Patients who did not fulfill the inclusion criteria for this study 
were managed with a set standard of care and treatment according to the VGHADT 
[114,115].  
Peer supporters received ART at the study clinics and were treated in the same way as other 
HIV patients according to the National Guidelines. Moreover, peer supporters received viral 
load (ExaVir Load) tests every 6 months, and they received a salary and transportation fees 
each month.  
Data were accessible only to research team, data manager and project coordinator. 
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5 MAIN FINDINGS 
5.1 RECRUITMENT AND OVERVIEW OF THE COHORT (II, IV) 
During the period of July, 2007 through November, 2009, a total of 640 HIV-infected 
participants (332 intervention patients and 308 control patients) were enrolled from 59 
communes (30 intervention communes and 29 control communes) in Ha Long City, Uong 
Bi Town, Dong Trieu district and Yen Hung district; 12 communes had no participants.  
Ha Long City has two study clinics (Ha Long CDC Life-gap based in the provincial hospital 
and Ha Long Health Center based in the Halong Health Center), responsible for treating the 
majority of patients (418; 65%), with clinics in Uong Bi (87; 14%), Dong Trieu (71; 11%) 
and Yen Hung (64; 10%) also participating in the study. All participants living in Dong 
Trieu district would receive ART in Uong Bi clinic as ART clinic in Dong Trieu was not 
chosen as a study clinic due to some logistic constraints, so the distribution of patients 
registering in the four study clinics were as follows: Ha Long CDC Life-Gap clinic (307; 
48%); Uong Bi clinic (181; 28%); Ha Long Health Center clinic (106; 17%) and Yen Hung 
clinic (46; 7%). On average, each commune had 11 patients. However, the number of 
patients was not distributed equally among communes: the Cao Xanh commune in Ha Long 
City has the highest number of patients (46) while 12 communes had only 1 patient each.  
After conducting a one-week pilot training session, we selected 14 qualified peer supporters 
(8 females, 6 males), aged between 25-44 years. The number of supporters was proportional 
to the number of intervention patients in each district/city. Seven peer supporters were based 
in Ha Long (191 patients); 3 in Uong Bi (51 patients), 2 in Dong Trieu (56 patients) and 2 in 
Yen Hung (34 patients). Each peer supporter was responsible for visiting between 10 and 20 
patients (Table 2). 
 




No. of peer 
supporters 
 

















10 (50) 191 (46) 10 (50) 227 (54) 20 (34) 
 
418 (65) 
Uong Bi  
(107,000) 
3 5 (45) 51 (58) 6 (55) 36 (42) 11 (17) 87 (14) 
Dong Trieu  
(163,000) 
2 8 (27) 56 (17) 5 (17) 15 (5) 13 (23) 71 (11) 




7 (23) 34 (10) 8 (28) 30 (9) 15 (25) 64 (10) 
Total 14 30 (51) 332 (52) 29 (49) 308 (48) 59 (100) 640 (100) 
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  By the end of the study, mean follow-up time was 20.4±7.2 months, 78% (501/640) of 
patients remained on ART, 11% (70/640) were dead, 10% (64/640) were lost-to-follow-up 
and 1% (5/640) had transferred to other clinics. Among the 64 lost-to-follow-up patients, 17 
(27%) had voluntarily withdrawn, 7 (11%) did not show up for three consecutive visits and 
40 (62%) were arrested and put in rehabilitation centers due to injecting heroin. Eleven 
patients were arrested during the ART treatment. However, they had continuous access to 
ART and then resumed their ART at the clinics after being released from the rehabilitation 
center, therefore they were not considered as lost-to-follow-up. The distribution of retention 
in care, dead, lost-to-follow-up and transferred patients was equally distributed in both the 


















Figure 13: Patient recruitment and follow-up status after 24 months 
640 patients enrolled 
(59 clusters) 




308 controls (29 clusters) 
32 lost-to-follow-up (10%) 
-  7 withdrawn 
- 3 did not show up for 
three consecutive visits 
















660 patients eligible 
(71 clusters: 36 interventions and 35 controls) 
- 20 did not give consent 
- 12 clusters had no patients  
(5 interventions, 7 controls) 
32 lost-to-follow-up (10%): 
- 10 withdrawn 
- 4 did not show up for 
three consecutive visits 
- 18 arrested 
 43 
5.2 BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS 
There were no significant differences observed between the two groups, apart from in those 
patients from the Ha Long CDC clinic (Table 3). 




Total   
(n=640) 
Control   
(n=308) 




n (%) n (%) n (%) 
Age  
Median (IQR) 31.9 (28.2-35.1) 31.7 (28.2-34.5) 32.1 (28.4-35.6)  
<35 years old 474 (74.1) 235 (76.3) 239 (72.0) 0.21 
>35 years old 166 (25.9) 73 (23.7) 93 (28.0) 
Sex Male 452 (70.6) 216 (70.1) 236 (71.1) 0.79 
Female 188 (29.4) 92 (29.9) 96 (28.9) 
Marital status Single 195 (30.5) 89 (28.9) 106 (32.0) 0.44 
Married/divorced 445 (69.5) 219 (71.7) 226 (68.1) 
ART-naïve status Naïve 606 (94.7) 289 (45.2) 317 (49.5) 0.35 
Non-naïve 35 (6.0) 19 (6.2) 16 (4.8) 
History of OIs Yes 182 (28.4) 91 (29.5) 91 (27.4) 0.55 
No 458 (71.6) 217 (70.5) 241 (72.6) 
Occupation Employed 493 (77.0) 243 (78.9) 250 (75.3) 0.31 
Unemployed 147 (23.0) 65 (21.1) 82 (24.7) 
Time to be known 
HIV-infected 
<6 months 156 (24.4) 69 (22.4) 87 (26.2) 0.31 
>6 months 449 (70.0) 220 (71.0) 229 (69.0) 
HIV transmission 
route (self-reported) 
IV Drug use 297 (46.4) 136 (44.2) 161 (48.5) 0.27 
Sexual and others 343 (53.6) 172 (55.8) 171 (51.5) 
History of IDU Yes 337 (52.7) 151 (49.0) 186 (56.0) 0.08 
No 303 (47.3) 157 (51.0) 146 (44.0) 
Viral hepatitis Yes 207 (33.7) 92 (31.1) 115 (36.2) 0.18 
No 407 (36.3) 204 (68.9) 203 (63.8) 
History of TB 
treatment 
Yes 99 (15.5) 53 (17.2) 46 (13.9) 0.24 




Yes 256 (40.0) 132 (42.9) 124 (37.3) 0.09 
No 
384 (60) 176 (57.1) 208 (62.7) 
WHO clinical stage 
Clinical stage 1 or 2 298 (46.6) 142 (46.1) 156 (47.0) 0.82 
Clinical stage 3 or 4 342 (53.4) 166 (53.9) 176 (53.0) 
BMI”  
18+ kg/m2 409 (64.0) 188 (61.0) 221 (66.7) 0.15 
<18 kg/m2 231 (36.0) 120 (39.0) 111 (33.3) 
Hemoglobin level 
<100g/L 73 (11.4) 33 (10.7) 40 (12.0) 0.61 
>100 g/L 520 (81.2) 253 (82.1) 267 (80.4) 
CD4 counts   
Median (IQR) 83 (29-176) 82 (27-183) 84 (30-168)  
<100 cells/µl 359 (56.1) 172 (55.8) 187 (56.3) 0.90 
>100 cells/µl 281 (43.9) 136 (44.2) 145 (43.7) 
VL at baseline  <100.000 copies/ml 426 (66.7) 209 (67.9) 217 (65.6) 0.54 
>100,000 copies/ml 213 (33.3) 99 (32.1) 114 (34.4) 
ART^ regimen 
D4T/3TC/NVP 533 (83.3) 258 (83.8) 275 (82.8) 0.75 
Other regimens 107 (16.7) 50 (16.2) 57 (17.2) 
Clinics 
Halong CDC 307 (48.0) 168 (54.5) 139 (41.9) 0.001 
Other clinics 333 (52.0) 140 (45.5) 193 (58.1) 
*OIs: opportunistic infections; IDU: Injecting drug use; TB: tuberculosis; BMI: Body Mass Index; ART: 
Antiretroviral therapy; VL: viral load. 
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5.3 ADHERENCE ASSESSMENT (IV) 
Among 3,915 self-report adherence forms collected quarterly for 24 months, there were 
2,033 (52%) forms collected from the intervention group and 1,882 (48%) forms collected 
from the control group, in total of 585 on-treatment patients who had at least one time for 
adherence assessment (91%); (304 interventions and 281 controls). The other 55 patients 
did not fulfill any adherence self-reported forms due to deaths or being lost-to-follow-up.  
Of 585 on-treatment patients, 285 patients (49%) reported missing at least one dose during 
24 months (153/304; 50% in intervention group and 132/281; 47% in control group; 
p=0.46). However, according to the definition of incomplete adherence in this study, which 
was patients missing more than one dose, only 30 incomplete adherence forms (14 
interventions and 16 controls) were reported from 27 patients (14 from the intervention 
group and 13 from the control group). As the results show, the rate of incomplete adherence 
among intervention patients of 14/304 (4.6%) was exactly the same as that of the control 
patients 13/281 (4.6%). According to the intention-to-treat analysis, the rate of incomplete 
adherence among collected adherence forms in intervention group of 14/2,656 (0.5%) was 
not significantly different to that of the control group 16/2,464 (0.6%) [RR=1.06; 95%CI 
(0.52-2.16; p= 0.88)].        
5.4 CLINICAL OUTCOME (IV) 
During the 24 months of follow-up, clinical outcomes improved by mean body weight 
having increased significantly from 50.2 ± 7.3 kg at baseline to 53.7 ± 7.9 kg at month 24 
(p< 0.001). However, there was no significant difference in gaining weights between the 
intervention and control groups (50.2 ± 6.8 vs 50.3 ± 7.7 kg at baseline, respectively; p=0.86 
and 53.5 ± 7.0 vs 53.9 ± 8.8kg at month 24, respectively; p =0.66). 
Our study showed the retention rate of patients on the ART was 78% after 24 months with 
no significant difference between the intervention and control groups (79% vs 78%; 
respectively; p=0.70).  
5.4.1 Mortality (II, IV) 
We followed up at the median time of 15.2 months (IQR 9.0-22.5) with 640 patients, the 
overall mortality rate was 60/640 (9%; 7.4/100 person-years). The majority of deaths (73%) 
occurred within 6 months and the probability of surviving after 3, 6, 9, 12 and 15 months 
was 95%, 93%, 92%, 91% and 90%, respectively. The median survival time for those who 
died was 79.0 days (IQR 29-185). The overall mortality in the intervention group (32/332; 
9.6%) was not different from the control group (28/308; 9.1%) (p=0.79) (Figure 14). 
Neither was there a difference in AIDS-related deaths (24 in intervention group and 25 in 
control group) (p=0.57) (II). 
When we continued following-up these 640 patients until 24 months (mean 20.4 months), 
there were a total of 70 deaths. The overall mortality rate was 11% (6.4/100 person-years) 
with no significant difference between the intervention and control groups (36/332; 10.8% 




Intervention   332  313 307 304 302   300 300 300 300 300 
Control   308  292 289 284 283   280 280 280 280 280 
Figure 14. Kaplan-Meier survival curves: no difference on survival between the intervention group 
and the control group (log-rank p = 0.79)  
5.4.2 Causes of death 
Most patients (n= 46; 77%) went to hospitals for admission and received care and treatment 
before dying. Most deaths were AIDS-related (n= 49 patients; 82%), and TB was the most 
common cause (40%), following were penicillium marneffei (8%), mycobacterium avium 
complex (8%), hepatic failure (8%). Only 13% of the tuberculosis-related death cases were 
diagnosed or had history of TB treatment before starting ART. Other non-AIDS related 
deaths were atributable to heroin overdose (8%), committed suicide (3%).   
5.4.3 Risk factors for death 
The following factors at baseline were associated with death during follow up: history of 
IDU, male, age >35 years, CD4 count <100 cells/µl, VL >100,000 copies/ml and 
hemoglobin level <10g/l (p <0.05 for all). In a multivariable Cox proportional hazard 
model, the following baseline factors were associated with an increased risk of AIDS-
related death: age >35 years, BMI <18kg/m
2
, clinical stage of 3 and 4, CD4 count <100 
cells/µl, hemoglobin level <100g/l, VL >100,000 copies/ml. 
5.4.4 Changed regimens 
There were 163 (25%) patients who had to change their ART regimens (within the first-line 
regimen) due to ADRs, of which the most common reasons for changing the regimens were 
peripheral neuropathy (104; 64%), rash (25; 15%), hepatitis (15; 9%) or TB treatment (9; 
6%). However, there was no significant difference between the intervention and control 
groups (89; 27% vs 74; 24%, p=0.47). Fifty four patients (8.5%) developed at least one OI 
or TB after 6 months of ART (8% in the intervention group and 9% in the control).  
Logrank p=0.79 
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Six (1%) patients switched to the second-line regimens (3 in the intervention group and 3 in 
the control); all of these switched after treatment at least 18 months after having 
confirmatory PCR VL >5,000 copies/ml. The overall mortality rate was 70/640 (11%; 
6.4/100 person-years) with no significant difference between the intervention and control 
groups (6.3/100 person-years vs 6.5/100 person-years, respectively, p >0.05).   
5.5 VIROLOGIC OUTCOMES (III, IV) 
5.5.1 Virologic failure in the 640 patients (IV) 
Among 640 patients, after 24 months of ART initiation, a total of 46 patients (7.2%) 
experienced virologic failure. There was no significant difference regarding virologic failure 
rates between the intervention (23/332; 6.9%) and control groups (23/308, 7.5%) [RR=0.93; 
(95%CI: 0.13-6.54); p=0.94] (Table 4). Also, among the 46 virologic failure cases in our 
study, 22 (48%) were secondary virologic failure (10 in the intervention group and 12 in the 
control group). 
Table 4: Impact of peer support on virologic failure at months 6, 12, 18 and 24 (n=640) 

















































































RR: Relative Risk 
The Kaplan-Meier curves showed no significant difference in time to virologic failure 
between intervention and control groups (Log-rank p-value = 0.77) (Figure 15).  
 47 
 
Figure 15. Log-rank test for equality of survival curves between intervention and control group  
Results are adjusted by other variables in the randomized groups:  age, gender, WHO 
clinical stage, baseline VL, baseline CD4 counts, ART-naïve status, history of IDU, TB 
history, history of OIs, having an HIV-infected family member, receiving ART at the Ha 
Long CDC clinic, changed ART regimen and incomplete adherence; all showed that the risk 
factors for developing virologic failure were ART-non-naïve status [aHR 7.0;(95%CI 3.3-14.7); 
p<0.01]; baseline VL >100,000 copies/ml [aHR 2.3;(95%CI: 1.2-4.3); p<0.05]; and incomplete 
adherence [aHR 3.1;(95%CI: 1.1-8.9); p<0.05] (Table 5).  
Table 5: Cox Proportional Hazards Frailty model 
 Bivariate Adjusted* 
Characteristics HR(95% CI) p-value aHR(95% CI) p-value 
Intervention group 1.0 (0.5;1.7) 0.94   
Male gender 2.0 (0.1;4.0) 0.05   
Age <35 years 0.7 (0.4;1.4) 0.37   
Severe HIV (clinical stage 3 or 4) 1.2 (0.6;2.1) 0.59   
History of IDU 1.9 (1.0;3.3) 0.04   
ART-non-naïve status 4.8 (2.4;9.4) <0.01 7.0 (3.3-14.7) <0.01 
TB history  1.6 (0.8;3.2) 0.15   
VL at baseline >100,000 copies/ml 1.6 (0.9;2.8) 0.13 2.3 (1.2-4.3) <0.05 
CD4 at baseline < 100 cells/µl 1.4 (0.8;2.5) 0.28   
Having an HIV-infected family 
member  0.5 (0.3;0.9) 0.03   
From Ha long OPC 1.0 (0.6;1.8) 0.91   
History of OIs 0.5 (0.2;1.0) 0.06   
Changed ART regimen 1.1 (0.5;-2.0) 0.85   
Incomplete adherence  2.4 (0.9;6.7) 0.09 3.1 (1.1-8.9) <0.05 
OIs: opportunistic infections; VL: viral load; IDU: Injecting drug use; TB: tuberculosis; ART: Antiretroviral 
therapy;  OPC: outpatient clinic; HR: Hazard Ratio; aHR: adjusted Hazard Ratio. 
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There was no significant effect of the clusters on the survival data, analyzed using 
likelihood-ratio testing the null hypothesis of no variance of the frailty effects (p=0.5 
>0.05).  
After enrollment, 35 (6%) patients admitted that they had experience of ART before the 
study started, of whom 14 (40%) patients were reported ART-non-naïve more than 2 weeks 
before study started; 21 patients (62%) had undetectable VL at baseline. As the study was 
intention-to-treat and the VL was analyzed after enrollment, these cases were still included 
in the study. After excluding these non-naïve patients, the statistical analyses among only 
605 ART-naïve patients (316 in the intervention group and 289 in the control) also showed 
no significant difference in virologic failure rates between intervention group and control 
group [6.3% vs 5.2%; respectively, RR=1.22; (95%CI: 0.63-2.37); p=0.56] (data not 
shown).     
5.5.2 Virologic failure in the 605 ART-naïve patients (III) 
When we look at only 605 ART-naïve patients, after 24 months, 35 (5.8%) patients 
developed virologic failure, of which 15 (43%) were primary virologic failure. The 
cumulative virologic failure rate among samples assessed with VL over 24 months was 
6.8% (95%CI 4.9-9.3).  
The virologic failure rates (VL >1,000 copies/ml) at months 6, 12, 18 and 24 among 605 
patients according to intention-to-treat analysis were 2%, 3%, 2%, 2% (Table 5), 
respectively, and among patients on treatment and accessed with VL were 3%, 4%, 3%, 4%, 
respectively (Figure 16).  
 
 
Figure 16. The viral suppression, blips and virologic failure rates among patients who accessed with 
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Of the patients that experienced treatment failure, only 6 were switched to the second-line 
regimen during the 24 months of follow-up. Patients with baseline VL >100,000 copies/ml 
were more likely to develop virologic failure than those with baseline VL <100,000 
copies/ml both by using Kaplan-Meier failure estimates (Log-rank p <0.001); (Figure 17) 
and in the flexible parametric survival model after the variable selection [aHR 2.26 (95%CI 
1.16-4.39); (p =0.016)]. 
 
 
Figure 17: Kaplan-Meier showed VL at baseline as a risk factor for virologic failure  
(Log-rank p-value <0.001). 
5.5.3 Virologic suppression rate and “Blips” (III) 
In the cohort of 605 ART-naïve patients, the virologic suppression rates at months 6, 12, 18 
and 24 among all patients according to intention-to-treat analysis were 76%, 72%, 67%, 
64% (Table 6), respectively, and among patients on treatment and accessed with VL were 
93%, 93%, 94%, 94%, respectively (Figure 16).  
“Blips” rates (VL 200-1,000 copies/ml) after 6, 12, 18, 24 months among all patients 
according to intention-to-treat analysis were 3%, 2%, 2%, 2%, respectively (Table 6) and 
among on-treatment patients who accessed to VL as 4%, 3%, 3%, 2%, respectively (Figure 
16).  
At baseline, 13 patients presented with a VL of <200 copies/ml and another 15 patients with 







Table 6: The virologic outcomes and the status of 605 patients after 24 months of follow-
up according to intention-to-treat analysis: 
Outcomes / Months  0m  
n, (%)  
6m  
n, (%)  
12m  
n, (%)  
18m  
n, (%)  
24m  
n, (%)  
Deaths (accumulated)  0  47 (8)  61 (10)  68 (11)  68 (11)  
Lost-to-follow-up 
(accumulated)  
0  16 (3)  32 (5)  50 (8)  65 (11)  
VL <200 copies/ml  13 (2)  460 (76)  433 (72)  406 (67)  386 (64)  
VL 200-1,000 copies/ml  15 (3)  20 (3)  14  (2)  11 (2)  10 (2)  
VL > 1,000 copies/ml  577 (95)  15 (2)  18 (3)  14 (2)  16 (2)  
VL tests missing  0  47 (8)  47 (8)  56 (9)  60 (10)  
Total 605 (100) 605 (100) 605 (100) 605 (100) 605 (100) 
5.6 IMMUNOLOGIC OUTCOME (IV) 
The median CD4 counts increased rapidly from 83 cells/µl (IQR 29-176) at baseline to 202 
cells/µl (IQR 121-311) at month 6, to 260 cells/µl (IQR 168-400) at month 12, to 305 
cells/µl (IQR 220-463) at month 18 and to 371 cells/µl (IQR 249-534) at month 24. The 
increase of median CD4 count from baseline to month 24 was 286 cells/µl (292 cells/µl in 
intervention group and 279 cells/µl in control group). However, there was no significant 
difference in increase of CD4 count between the intervention and control groups (p>0.05; t-
test and Wilcoxon rank-sum test) (Figure 18).  
 
 
Figure 18: Median trends of CD4 counts over time between intervention and control groups 
Patients with baseline VL >100,000 copies/ml [adj.Coeff. (95%CI): -0.9(-1.5;-0.3); p<0.01] 
and baseline CD4 count <100 cells/µl [adj.sq.Coeff. (95%CI): -5.7(-6.3;-5.1); p<0.01] had a 
significantly slower increase of CD4 count compared to the other patients. Contrarily, 
patients having an HIV-infected family member had a significantly faster increase in CD4 
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count compared to those who did not have an HIV-infected family member [adj.sq.Coeff. 
(95%CI): 1.3(0.8;1.9); p<0.01] (Table 7).         
Clusters did not affect the analysis. There was no effect of the clusters in the longitudinal 
analysis shown through the likelihood-ratio test to compare two models: one with the 
random effect of the clusters and the other without (nested into it): p-value =0.72 (>0.05).  
The baseline VL >100,000 copies/ml is hence a risk factor for both virologic failure and 
significantly slower increase in CD4 count. Also, again the results show there is no 
significant difference in the CD4 trends between the intervention and control groups 
(p=0.69). 
Table 7:  Mixed effects model of selected variables in relation to CD4 trends (3 levels) 
with random intercept and random slope crude model adjusted by the variables 
 Bivariate Adjusted 
Characteristics Coeff(95%CI) p-value Adj.sq.Coeff(95%CI) p-value 
Intervention group 0.2 (-0.6;-0.9) 0.69   
Female gender -3.0 (-3.8;-2.3) <0.001   
Age <35 years -0.3 (-1.1;-0.6) 0.54   
Severe HIV (clinical stage 3 or 4) -2.1 (-2.8;-1.4) <0.001   
History of IDU -2.1 (-2.8;-1.4) <0.001   
ART-non-naïve status 0.8 (-0.8;2.5) 0.32   
TB history -0.2 (-1.2;0.8) 0.68   
VL at baseline >100,000 copies/ml -2.8 (-3.6;-2.0) <0.001 -0.9 (-1.5;-0.3) <0.01 
CD4 at baseline <100 cells/µl -6.8 (-7.4;-6.3) <0.001 -5.7 (-6.3;-5.1) <0.001 
Having an HIV-infected family 
member  2.5 (1.8;3.3) <0.001 1.3 (0.8;1.9) <0.001 
From Ha long CDC OPC -0.5 (-1.2;0.3) 0.22   
History of OIs 1.1 (0.3;1.9) <0.01   
Changed ART regimen 1.0 (0.1;1.8) <0.05   
Incomplete adherence (missing more 
than one doses in 24 months) -1.3 (-3.1;0.5) 0.15   
Month 0.4 (0.4;0.4) <0.001 0.39 (0.38;0.41) <0.001 
OIs: opportunistic infections; VL: viral load; IDU: Injecting drug use; TB: tuberculosis; ART: Antiretroviral 
therapy; OPC: outpatient clinic; Coeff: Coefficient; adj.sq.Coeff: adjusted square Coefficient. 
5.7 COMPARISION BETWEEN EXAVIR LOAD AND TAQMAN PCR (III) 
Overall 60 samples were quantified with both ExaVir Load and TaqMan PCR. Of these 44 
(73%) had detectable virus. The median VL was 36,025 (IQR 200-165,770) copies/ml by 
ExaVir and 74,900 (IQR 41-208,000) copies/ml by Taqman. There were 15 samples (25%) 
with undetectable VL by both assays, all from 16 treated patients. One sample showed a VL 
of 45 copies/ml by TaqMan but an undetectable VL by ExaVir Load.  
The Spearman coefficient correlation between the two assays was r
2
 = 0.97 [95% CI (0.95 – 
0.98); 2-tailed p-value <0.0001], (Figure 19). There was a good agreement between the two 
assays with a mean of difference in log VL of 0.34 [95% CI (-0.35 ; 1.03)] (Figure 20).  
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Figure 19. Correlation between Roche TaqMan and Cavidi ExaVir Load assays. Undetectable 
values are scored as 40 copies corresponding to the lower limit of RNA quantification. The 
Spearman correlation coefficient was r
2
 =0.97 (95%CI 0.95–0.98, p<0.0001). The equation for the 
regression line is log ExaVir Load = 0.8931 log TaqMan + 0.1773  
 
 
Figure 20. The Bland – Altman plot analysis to compare between Roche TaqMan and Cavidi ExaVir 
Load assays. The mean of difference in log VL results between two assays was 0.34 [95% CI 
(-0.35 ; 1.03)].  
5.8 SENSITIVITY AND SPECIFICITY OF EXAVIR LOAD (III) 
Among 45 patients had detectable VL with TaqMan PCR assay (> 40 copies/ml), there were 
44 patients had detectable VL with ExaVir RT assay. Therefore, the sensitivity of the 
ExaVir RT assay relative to the TaqMan PCR assay was 44/45 = 98%.  
Similarly, among 15 patients had undetectable VL with TaqMan PCR assay (<40 
copies/ml), there were 15 had undetectable VL with ExaVir RT activity. Therefore, the 
specificity of the ExaVir RT assay relative to the TaqMan PCR assay was 15/15=100% 
(Table 8). 
Bland-Altman plot: Exavir versus Roche






































Table 8. ExaVir load values in relation to amount of HIV RNA copies detected
 
Range (copies/ml) 
ExaVir RT assay 
(n, %) 
TaqMan PCR assay 
(n %) 
<40 - 15 (25) 
40 - 199 16 (27) 1 (2) 
200 - 999 1 (2) 2 (3) 
1,000 - 4,999 6 (10) - 
5,000 - 99,999 18 (30) 15 (25) 
100,000 - 410,000 12 (20) 17 (28) 
410,000 - 10,000,000 7 (11) 9 (15) 
> 10,000,000 - 1 (2) 
Total 60 (100) 60 (100) 
 
5.9 DRUG RESISTANCE MUTATIONS IN ART-NAÏVE PATIENTS (I) 
Were found that 100% of patients were infected with HIV-1 subtype CRF01_AE with 
≥95% bootstrap support. The 63 included samples all originated from ART-naïve 
individuals and most viruses were fully susceptible to all protease and reverse transcriptase 
inhibitors; 38 (60.3%) had no resistance associated mutations at all, while 20 sequences 
(31.7%) had one or two polymorphic mutations that frequently occur in untreated patients. 
Four patients were, however, infected with viruses carrying transmitted resistance 
mutations, giving a TDRM prevalence of 6.3%. An overview of all detected resistance 
associated mutations is shown in Table 9.   
Table 9. Number of patients with different resistance associated mutations. 





mutations PI mutations 
1 (1.6) L210W None None 
1 (1.6) L74I None L10I 
1 (1.6) V75M None None 
1 (1.6) None Y181C L10I 
1 (1.6) None A98G None 
2 (3.2) None V179D None 
2 (3.2)  None V106I None 
7 (11.1) None V106I L10I/V 
9 (14.3) None None L10I/V 
38 (60.3) None None None 
60 (100%)    
Mutations on the TDRM list (Bennett, 2009) are shown in bold text. Minor resistance 
mutations present on the IAS-USA list are shown in regular format. 
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Three of the TDRMs present in the analyzed samples confer reduced susceptibility to 
NRTIs; L74I (n=1) and V75M (n=1) confer low-level resistance to ddI (both), d4T (V75M) 
and ABC (L74I), while L210W (n=1) causes a low-level of resistance to all NRTIs except 
3TC and FTC. The fourth TDRM was Y181C (n=1), which provides intermediate to high 
level of resistance to all NNRTIs. Minor mutations found for reverse transcriptase were: 
A98G (n=1), V179D (n=2), V106I (n=9), while L10I/V was found in the protease region of 
18 sequences. No clinically significant resistance mutation for protease inhibitors was found 
in this study. 
5.10 PHYLOGENETIC RELATIONSHIPS AND TMRCA CALCULATIONS (I) 
Sixty-three pol-sequences from ART-naïve Vietnamese HIV-patients were aligned with 190 
CRF01_AE and four subtype B sequences retrieved from public and local databases. The 
initial analysis in BEAST revealed three clearly demarcated clades which all had a posterior 
probability support=1. These defined three taxons which were used for the subsequent 
tMRCA calculations; ‘CRF01_AE’ (which included all the Vietnamese samples plus the 
190 CRF01_AE reference sequences), ‘Vietnam large clade’ (60/63 Vietnamese strains in 
this study), and ‘Vietnam small clade’ (three Vietnamese samples that clustered separately 
from the others), (Figure 21).   
 
Figure 21: Phylogenetic trees showing the nodes used for tMRCA calculations and the intermixture 
of strains from intravenous drug users and sexually infected patients in Northern Vietnam.  
The small inset tree shows all 257 strains with the Vietnam large and small clades encircled. In the 
larger tree some clades have been collapsed for clarity. The branch length corresponds to the year 
of sampling. Node markings: Red circles= posterior probability >0.99; Blue circles: Posterior probability 
>0.90. Tip markings: Filled circles=Intravenous drug users, Open circles: Sexually infected patients. No tip 




To our knowledge, this is the first cluster randomized trial to assess peer support on 
virologic failure among HIV-infected patients starting ART in Vietnam and probably in 
Asia. The DOTARV project began in 2006 in Quang Ninh province when the HIV 
epidemic had reached its highest prevalence and the ART programs supported by 
PEPFAR and Global Fund had been scaling up rapidly. Our studies have sketched a 
picture of ART treatment in the North of Vietnam and have been summarized in the 
following issues:  
6.1 ART TREATMENT OUTCOMES 
 The study has shown a comparably low virologic failure rate, low mortality and high 
retention rate after 24 months of follow-up. These results indicate that a well-funded and 
well-organized ART program implemented through PEPFAR and Global Fund in Vietnam 
can be rolled out successfully in remote and resource-limited settings. 
6.1.1 Virologic outcomes (III, IV) 
6.1.1.1 Virologic failure (III, IV) 
As a primary endpoint of the cohort, after 24 months of follow-up, among 640 patients, the 
cumulative rate of virologic failure was (7.2%) (IV), and among 605 ART-naïve patients, 
the cumulative virologic failure rate was 6.8% (III). The virologic failure rates in our 
studies were lower compared to that in other countries (15 to 20%) [44,54,134,135] and by 
our estimation, when the study was planned (20%). In sub-Saharan African countries, 
findings from a systematic review showed an overall virologic failure rate (VL >1,000 
copies/ml) was 24% within 12 months of ART [136]; the highest rate (43%) was seen in a 
Rwanda [137]. Report about virologic failure rates in Vietnam is still limited. A recent study 
in Hai Phong showed the virologic detectable rate (>400 copies/ml) was 23% after 14 
months  [118]. 
In both cohorts (640 patients and 605 ART-naïve patients), we did not see significant 
difference between the intervention and control groups in cumulative virologic failure rate 
and time to virologic failure.   
6.1.1.2 Virologic suppression rate (III) 
In a cohort of 605 ART-naïve patients, the virologic suppression rate at month 24 was 94% 
among on-treatment patients and was higher than reported from other resource-constrained 
settings, including Uganda (86%) [138], Malawi (84%) [139] and Cameroon (52%) [55]. In 
sub-Saharan African countries, findings from a systematic review showed an overall 
virologic failure rate (VL < 400 copies/ml) was 67% within 24 months of ART [140]. 
Recent studies in Vietnam reported that the suppression rates among IDU populations were 
73%  in Hanoi [141] and 70% in Ho Chi Minh City [117].  In neighboring countries, at 24 
months, 88% (306/346) of patients had achieved VL <400 copies/ml in Cambodia [142] and 
15% (55/345) had virologic failure (>400 copies/ml) in Thailand [143]. However, most of 
these studies reported on-treatment results that were analyzed in a cross-sectional fashion 
and included both ART-naïve and non-naïve patients (Table 10).  
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The high virologic outcomes in our study may be explained by several factors including that 
the patients were ART-naïve and that the VL results were reported to the treating doctors 
because knowledge about viremia may result in intensification of the adherence support, 
both for intervention and control group patients. 
Table 10: Summary of virologic failure and suppression rates in different studies:  











Our study[IV] Quang Ninh – Vietnam > 1,000 640 7.2 24 months 
Huong DTM [118] Hai Phong - Vietnam >  400 100 23 14 months 
Castelnuovo B. [44] Uganda > 10,000 559 17.8 48 months 
Meya D [54] Uganda > 1,000 496 8 13 months 
Steven JR [135] Uganda > 400 1,133 9.9 44.4 months 
Fox MP [134] South Africa > 400 19,645 9.9 1.8 years 
Fischer A [137] Rwanda > 400 60 43 14 months 
Tsuchiya [143] Thailand > 400 345 15 24 months 
Virologic suppression 
Our study [III] Quang Ninh – Vietnam < 200 605 94 24 months 
Jordan MR [141] Hanoi -Vietnam < 1,000 100 73 13.6 months 
Trinh TT [117] HCMC - Vietnam < 250 228 70 26 months 
Ferradini L [142] Cambodia <400 346 88 24 months 
Laurent C [55] Cameroon < 40 884 52 24 months 
Chang LW [138] Uganda < 400 360 86 10 months 
Ferradini L [139] Malawi <  400 398 84 8.3 months 
Barth RE [140] sub-Saharan Africa < 400 5,690 67 24 months 
 
6.1.1.3 Low viremia “Blips” (III) 
It has been reported that many patients receiving ART experience intermittent episodes of 
detectable low-level viremia ("blips"), which may result in drug resistance, lead to costly 
repeat measurements of VL, and trigger alterations in therapy [144,145]. In our study, viral 
blips (VL 200-1,000 copies/ml) were identified at a low rate of 3% of all samples (55/1,803) 
and 2% of patients at month 24 (10/605). It should be noted, however, that as the detection 
limit using ExaVir Load is 200 copies/ml, then “minor” blips under this level cannot be 
detected, so the blip rates in our study might not be comparable to those obtained from 
studies done by PCR that can measure down to 50 copies/ml [48]. However, the blips in our 
study did not show any significance in predicting subsequent virologic failures despite the 
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higher cut-off and the clinical relevance of using a higher sensitivity VL assay in the 
Vietnamese setting can therefore be questioned. 
6.1.1.4 Undetectable viral load at baseline (III, IV) 
We also found that at baseline, 34 patients who had undetectable VL (15; 4.5% in the 
intervention group and 19; 6.2% in the control group; p=0.23). Their median CD4 count at 
baseline was 94 (IQR 35-164) cells/µl. Among those, 21 (62%) patients were non-naïve and 
another 13 patients were found to have undetectable VL at baseline and all of them claimed 
that they were naïve, and their VL was kept undetectable throughout the whole term of the 
study. It is noted that one patient living in Yen Hung district, his CD4 counts were always 
high with the values at baseline, 6, 12, 18, and 24 months were 1,737 cell/µl; 1,401 cell/µl; 
1,898 cell/µl; 354 cell/µl and 418 cell/µl, respectively.   
The mechanisms, by which a small percentage of HIV-1 infected individuals known as 
“elite suppressors” or “elite controllers”, are able to control viral replication are not fully 
understood. Early cases of viremic control were attributed to infection with defective virus, 
but subsequent work has demonstrated that infection with a defective virus is not the 
exclusive cause of control. Replication-competent virus has been isolated from patients who 
control viral replication, and studies have demonstrated that evolution occurs in plasma 
virus but not in virus isolates from the latent reservoir. Additionally, transmission pair 
studies have demonstrated that patients infected with similar viruses can have dramatically 
different outcomes of infection. Therefore, an increased understanding of the viral factors 
associated with control is important to understand the interplay between viral replication 
and host control, and has implications for the design of an effective therapeutic vaccine that 
can lead to a functional cure of HIV-1 infection [146,147]. 
6.1.1.5 Factors associated with virologic failure (III, IV) 
Our study showed that ART-non-naïve status, high baseline VL ( >100,000 copies/ml) and 
incomplete adherence (missing more than one dose during 24 months) were risk factors for 
virologic failure. Also high VL (> 100,000 copies/ml) at baseline can be a predictor for the 
slower increase of CD4 counts and mortality [148]. Our findings were in line with other 
studies found that poor adherence and high VL at baseline is a predictor for virologic failure 
during ART [117,149,150]. Contrarily, studies in Thailand show low baseline CD4 count 
and race/ethnicity were independent predictors of virologic response, however, baseline VL 
and gender were not [151]. Aother study in Thailand showed that having a child was 
significantly associated with a lower rate of virologic failure [143].  
 
6.1.2 Immunologic outcomes (IV) 
As shown in our study, CD4 counts responded well after 24 months of ART (overall 
increase of 286 cells/µl). This finding is in line with other studies that show how CD4 cell 
counts increased quickly, in particular after 6 months of ART [55,152]. However, there was 
no significant difference between the intervention and control groups in CD4 trends after 
adjustment (p=0.69). As well as from the VL at baseline >100,000 copies/ml, the other 
factors also predict the increase of CD4 counts was a baseline of CD4 counts <100 cells/µl 
and having an HIV-infected family member. In a study in Thailand, CD4 count at baseline 
and changes in CD4 count were important in predicting CD4 counts ≤200 cells/μl [151].  
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In our study, after 24 months we found 45 patients (7%) had immunologic failure, of whom 
23 (6.9%) were in the intervention group and 22 (7.1%) in the control group (no significant 
difference, p >0.05). Also, there was a high discordance rate (71%) between immunologic 
and virologic failures. Only 13 patients (29%) had both immunologic failure and virologic 
failures (p <0.001).   
6.1.3 Mortality (II, III, IV) 
6.1.3.1 Mortality rate 
This study showed that the mortality rate among Vietnamese treatment-naïve patients 
initiating ART was 9% (7.4/100 person-years) during the first year, (II) and 11% (6.4/100 
person-years) during second years (IV), which is lower or similar to other studies in LMICs 
[55,138,139,153,154,155], [68,156,157]. In high-income countries, the death rate after ART 
initiation in generally was lower (1-5%) [71,158,159]. It is debatable whether the lower 
mortality in high-income context is due to more potent ART drugs, earlier cause detection, 
more thorough follow-up, or more probably, a combination of these factors [146,147]. 
There was no significant difference in mortality rate between the intervention and control 
groups after follow up either 15.2 (II) months or 24 months (IV).  
6.1.3.2 Late presentation and early mortality (II) 
Most of the deaths (73%) occurred within 6 months after initiation of ART. This finding is 
consistent with other studies in that early mortality is related to late detection of HIV when 
patients are severely immune-suppressed [3,69,70,71,156,160]. A major challenge is to 
identify HIV infected patients earlier, before severe immunodeficiency and AIDS develop. 
In our study, the problem with late identification of the patients was further exacerbated 
because patients had to wait a considerable amount of time from registration to ART 
initiation, a median of 2.3 months. Consequently, during this time, the median CD4 count 
decreased from 110 cells/µl to 41 cells/µl. This delay, which may have caused excess 
mortality, could be due to several factors: a) a fixed amount of patients were initiated on 
ART every month in each clinic, causing the accumulation of patients with severe immune-
suppression, b) difficulties in retention of care for patients with CD4 counts above 200 
cells/µl, which was the threshold for initiating ART; and c) patients with TB had to 
complete 2 months of intensive phase TB treatment before initiation of ART as 
recommended in the VGHADT. All of these possible causes are related to the health 
delivery structure and may hence be prevented; for example, promoting HIV testing or early 
timing of ART initiation during TB therapy could significantly reduce death rates [156,161], 
as could a more flexible system for initiating ART when indicated, instead of allowing only 
a fixed number of patients each month, as well as improved follow-up with patients who did 
not meet the inclusion criteria for ART.   
Many high- income countries are following the guidelines that recommend a CD4 count 
threshold of 350 cells/µl for initiating ART [42,162]. This recommendation is based on 
evidence that early initiation of ART may reduce sexual transmission, especially among 
sero-discordant couples [40], reduce the incidence of OIs and death [163], as well as 
improve the retention in care for those tested early [164]. However, in most LMICs, patients 
are generally diagnosed late. As seen in our study, there is limited access to ART even for 
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severely immune-suppressed patients, due to the intensification of the constraints on 
treatment. However, according to WHO recommendations, VGHADT has been revised to 
increase the CD4 threshold for initiating ART to 250 cells/µl in 2009 [115] and to 350 
cells/µl 2011 [116].  
Men were overrepresented among the patients who died (90%) and presented at the 
outpatient clinics later than women, with more severe immune-suppression and significantly 
lower CD4 counts (61cells/µl vs 143 cells/µl; p <0.001). A majority of men who died in our 
cohort had a history of IDU (65%). It is also known that active IDU can lead to poor ART 
adherence, and this is therefore associated with treatment failure and mortality [165,166].  
The relatively low death rate among women (3.2%) and high proportion of widows (40%) 
highlights the dynamic of the epidemic in Vietnam where men are commonly infected with 
HIV through IDU and then transmit the virus to their spouses [167]. Another reason for this 
disparity is because women are diagnosed earlier than men due to the screening of their 
partners (symptomatic men) or as a part of antenatal testing [69,168].  
6.1.3.3 Causes of death (II) 
Our study showed that nearly a half of the causes of death were attributable to TB. We also 
noted that two-thirds of the patients who died with TB had been referred to the TB 
provincial hospital and received TB treatment for a median period of 1.3 months. These data 
clearly suggest that many patients had an ongoing TB infection that was not revealed at a 
baseline clinical examination, but was probably unmasked by IRIS after initiation of ART 
[169]. A possible explanation is that a low median CD4 count (41 cells/µl) at the initiation 
of ART made TB diagnosis more difficult as it had weakened the inflammatory reaction 
that normally causes overt symptoms. Among 70 deaths after 24 months of ART initiation, 
two cases had primary virologic failure (both VL values were >100,000 copies/ml at 6 
months), however they both died of pulmonary TB. 
The prevalence of hepatitis B or C or both B and C in our cohort was 8%, 33%, and 3%, 
respectively and hepatic failure accounted for 8% of all AIDS-related deaths. The high 
prevalence of HBV or/and HCV co-infection among male drug users has previously been 
reported in Vietnam [108,166]. Hepatitis co-infected with HIV makes ART more 
complicated, as most of the liver damage is mediated by the immune response, which 
gradually improves. Hence proper and early management of hepatitis paralleled with 
initiation of ART is needed to prevent hepatic-related death among AIDS patients.  
Penicillium marneffei, which accounted for 8% of the mortality, is one of the most common 
OIs in South East Asia among severe immune-suppressed HIV-persons [108,170]. When 
ART is initiated, P. marneffei infections are often unmasked through IRIS. Diagnosis of P. 
marneffei in most cases was clinically based on skin lesions. However, it is known that 
about 30% of those with P. marneffei do not present with skin lesions [112,170], therefore it 
is possible that P. marneffei has been under-diagnosed.    
In high-income countries, there has been a shift in the causes of death toward non-AIDS 
related causes [4,171,172]. However, our study showed only 18% of deaths were non-AIDS 
related, in which the majority were heroin overdose (all males) and suicides. Thus, a 
comprehensive care and treatment approach including socio-psychological care and harm 
reduction programs need to be intensified [111].        
 60 
IRIS was not diagnosed in any patient in our study although it was possibly one of the major 
causes of death. This might be due to a limited capacity to diagnose IRIS among health-care 
providers [169]. In addition, patients may have developed IRIS symptoms but not shown up 
at the clinics immediately; instead, they waited until their monthly appointment dates to 
collect their medicine. Obviously, IRIS is known to be a major problem in resource-limited 
settings, due to a high incidence of severe immune-suppression at ART initiation and a high 
underlying prevalence of TB and other OIs [169,173]. Therefore, improving the capacity to 
diagnose IRIS, as well as advising patients to seek health care if new symptoms occur after 
initiation of ART, is needed to decrease mortality in the first few months of ART.  
6.1.3.4 Risk factors for death (II) 
Our results showed that old age, clinical stage 3 or 4, low BMI, low hemoglobin level and 
CD4 count and high baseline VL were the risk factors for AIDS-related deaths. These 
findings are expected and similar to other studies [3,70,157,174]. Importantly, these 
indicators may be used to identify patients at higher risk for early mortality and therefore in 
need of more thorough assessment of OIs and IRIS through frequent clinical visits during 
the first 6 months of ART. 
6.1.4 Retention in care (II, III, IV) 
High retention rate in care (78%) after 24 months reflects not only an improved health care 
system and ART programs in Vietnam, but also effective care and support activities in the 
community to motivate and engage patients in care. A recent study in Vietnam conducted 
among 4,531 adults and 313 children showed that 81.2% and 84.4%, respectively, were still 
on ART after 12 months [81].  
Data on the proportion of people who remain on ART over time in low- and middle-income 
countries continue to show that most discontinuation of ART occurs within the first year of 
starting therapy. The average retention rate at 12 months after initiating ART was 81% (92 
reporting countries), 75% at 24 months (73 countries) and 67% at 60 months (46 countries) 
[7]. Our study results were similar with the retention rate in Thailand (80.8% after 5 years) 
[175], Cambodia (80% after 4 years ) [154] and higher compared to other studies in sub-
Saharan Africa with the same 24 months of follow-up: Uganda (72%) [138] and Malawi 
(66%) [139]. Another systematic review of 74,192 patients of 13 sub-Saharan African 
countries showed the retention in care was 61.6% after 24 months [176]. Other studies also 
showed that engagement of HIV care is associated with improved clinical, virologic and 
immunologic parameters and survival outcomes [177,178]. Therefore, retaining HIV-
infected patients in care has become a public health issue to ensure the success and 
sustainability of ART programs [179].    
6.1.5 Impact of peer support on treatment outcome (II, IV) 
6.1.5.1 Impact of peer support on mortality (II) 
It has been claimed that adherence support counteracts treatment failure and the 
development of drug resistance [110,180] although no well-designed randomized controlled 
trials have yet been published. However, very little is known about the impact of peer 
support on ART outcome. In our study, there was no significant difference in mortality rate 
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between the intervention and control groups and this implied that enhanced treatment 
support had no impact on the mortality rate at the early stage of ART. However, it should be 
noted that the aim of our randomized controlled trial is to assess the long-term effect of peer 
support on virologic failure and the subsequent HIV drug resistance development. All 9 
(15%) cases who died after 6 months of ART initiation shown by undetectable VL implies 
that the majority of patients died due to either the severe clinical status at baseline or 
development of immune reconstitution inflammatory syndrome (IRIS), hence a positive 
effect of ART adherence enhanced by peer supporters on early mortality may not be 
expected.  
Autopsy is the most reliable way to confirm causes of death. In one UK study, autopsies of 
115 deceased HIV patients showed that 36% of all OIs were missed and in 70%, the 
primary diagnosis was changed [181]. However, considering that autopsy is rare and 
difficult to perform in Vietnam, especially among HIV-infected persons, the information 
about causes of death in our study was only obtained from medical records and verbal 
autopsy questionnaire interviews.      
6.1.5.2 Impact of peer support on virologic and immunologic outcomes (II) 
Our study might answer the research question in that there was no impact of peer support 
intervention on virologic and immunologic outcomes and mortality after 24 months of 
follow-up. This result could be explained by: i) the ART programs in Vietnam have been 
well funded and implemented through international donors including PEPFAR and Global 
Fund. Before ART was initiated, all patients had to be assessed for ART readiness, name a 
supporting family member and attend three adherence counseling sessions according to 
VGHADT [114]. For every visit, the slogans “100% adherence” or “taking ARV or death” 
were constantly emphasized and enhanced by the adherence counselor at OPC to raise 
awareness of the benefits to patients in adhering to drugs for life; ii) there was no significant 
difference in the self-report adherence rate between the two groups; iii) the eventual effect 
of the intervention might also be masked by a “ceiling effect” in which the control group 
also received a sufficient adherence support from the OPCs and the community-based 
programs. Quang Ninh, with a comparable high HIV prevalence, was one of the 9 selected 
provinces in Vietnam receiving PEPFAR support in order to set up “comprehensive care, 
treatment and support” programs, which were very active during the time of the project 
implementation. Therefore, PLHIV in Quang Ninh might be provided with additional 
support by projects run by other non-governmental organizations (NGOs) including those 
from the “Pact”-associated organizations funded by PEPFAR. The availability of 
community-based activities provided by groups such as the “the Bright Future”, “the Cactus 
Flowers”, “the Shared Feelings”, “community outreach groups”, and “home-based care 
teams” might have constituted a “contamination” where patients in the intervention group 
could meet and share adherence experiences with patients in the control group. As a result, 
both intervention and control groups might receive similar adherence support.  In our study, 
400 (63%) patients lived with their parents and other family members who might also play 
an important role as “internal supporters” to support patients in taking ARVs, hence the 
social context of the patient might be an important predictor for treatment outcome; v) 
telecommunication technology (mobile phones) could be a good tool in enhancing 
adherence [182,183,184,185]. A trial in Kenya showed that an “SMS reminder” 
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significantly improved ART adherence and rates of virologic suppression compared to the 
control groups; hence mobile phones might be an effective tool to improve patient outcomes 
in resource-limited settings [184], as is currently being assessed by a trial in India [185]. In 
our study, 90% of patients in both groups of our study possessed a mobile phone, which 
could be used as a tool to improve adherence. A recent qualitative study conducted among 
1,016 PLHIV in 3 cities Hanoi, Hai Phong and HCMC showed that mobile phone-based 
ART adherence could be a feasible, preferable tool for patients [186].      
In our study, we only reported data to the 24-month-follow-up; hence the sustained or long-
term effect of the adherence support intervention cannot be excluded. A recent study in 
Uganda has also shown that peer health care intervention had no impact on cumulative risk 
of virologic failure and virologic outcomes on short-term ART and suggested that it might 
be best suited for patients who have taken ART for longer periods, especially as it may 
mitigate the effects of “treatment fatigue” as patients tire of continually taking ART [99]. 
Therefore, to assess the sustained effect of the peer support intervention in our cohort, 
further research to continue following up patients with VL and CD4 count monitoring up to 
at least 48 months is needed.  
6.2 EFFICACY AND FEASIBILITY OF EXAVIR LOAD MONITORING (III): 
Our study is the first to complete a prospective, longitudinal study using a simple- and low-
cost VL to monitor virologic response to ART among treatment-naïve patients in Vietnam 
with advanced immunodeficiency at baseline (median CD4 count was 84 cells/µl).  
There may be several reasons to the favorable virologic outcomes in our study including 
that the patients were treatment-naïve and that the results were communicated to the treating 
doctor. However, according to the Vietnam National Guidelines [115], only six among 35 
virologic failure subjects (17%) were switched to the second-line ART. It is still possible 
that the information about the VL results could have contributed to the positive treatment 
outcome because increased knowledge about viremia may result in intensification of the 
adherence support. 
 The Vietnam - Sweden Uong Bi General Hospital was built in the 1980s. Most of the 
laboratories and equipment are kept nearly “original” from when it was built. However, 
high standard laboratory equipped for PCR technology is not available, so the ExaVir Load 
methodology was set up and implemented in the existing facilities. An advantage with the 
ExaVir Load assay is that it does not require advanced laboratories or equipment, and 
therefore it can be conducted in a district or provincial laboratory [45,59]. A constraint of 
the assay is the three day turn-around time and that is performed in batches of 30 samples 
only.  
In our study, the ExaVir assay showed a strong correlation with the Cobas TaqMan assay. 
This result was also reported in other studies performed in central laboratories or in research 
settings in Australia [57], India [59], the UK [63] and the USA [187]. Similarly, results have 
been obtained from a several studies in decentralized laboratories in China [62], Botswana 
[60] and Kenya [188]. However, no prospective longitudinal study has earlier been 
conducted in a decentralized routine laboratory setting. Our study, with 2,408 samples in a 
cohort of 605 treatment-naïve patients followed up for a median of 20.7 months has been 
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known as the largest and longest cohort study using this simple methodology to monitor 
virologic outcome of ART. 
Cost-effectiveness studies have shown that adding VL monitoring is cost-saving when 
second-line regimens are available but this is dependent on the VL testing cost and the 
expenditures for managing virologic failure [62,189,190,191]. In a South African study, a 
reduced cost of VL from US$80 to US$20 decreased the incremental cost-effectiveness 
ratio (ICER) from approximately US$5,000 to US$1,635 [190]. The interventions with an 
ICER of between one and three times the gross domestic product (GDP) per capita are 
considered cost-effective. Therefore, extrapolating to Vietnam (US$1,224 GDP per capita in 
2011 [192]), the use of the RT assay would be considered a cost-effective intervention. 
Rather than considering VL to be an unaffordable luxury, efforts should be made to ensure 
that simpler and cheaper testing alternatives, such as the ExaVir Load, are developed and 
implemented in resource-limited settings. 
 
6.3 TRANSMITTED DRUG RESISTANCE AMONG ART-NAÏVE PATIENTS 
Our study showed the resistance mutations that were detected, including Y181C (in a 
sexually infected patient), L210W (in an IDU), L74I (in an IDU) and V75M (in a patient 
with unknown mode of transmission), are in line with what could be expected, as the first-
line treatment in Vietnam since the nationwide PEPFAR-funded ART roll-out in 2005 has 
been d4T/AZT + 3TC + NVP/EFV. Protease inhibitors have not been widely used, which is 
mirrored in the absence of PI-associated mutations. The total TDRM prevalence observed in 
this study (6.3%) is slightly higher compared with other recent studies performed in the 
same geographic region: China 3.8% [193], Vietnam 2.9% [36], Thailand 2% [32], and 
Cambodia 1.5% [194]. However, none of the study participants had viruses harboring more 
than one TDRM and the total prevalence for the three relevant drug classes were thus 4.7% 
(NRTI), 1.6% (NNRTI) and 0% (PI), all falling below the 5% threshold level defined by 
WHO [34]. It should be noted that among four patients with TDRMs, one patient with 
V75M mutation was lost-to-follow-up after 3 months of ART initiation, and three other 
patients with Y181C, L210W and L74I had constant VL >1,000 copies/ml at month 6, 12, 
18, 24, however they reported VL < 5,000 copies/ml confirmed by PCR, therefore they have 
not been switched to second-line regimen yet after 24 months, despite their CD4 counts 
have not declined but instead are steadily increasing.      
Nonetheless, apart from the patient who had virus with the Y181C mutation, the TDRMs 
detected in our cohort of ART-naïve patients in North Vietnam are of limited clinical 
importance and do not rule out the use of the standard first-line treatment regimen. 
However, in view of the increasing use of different antiretroviral drugs in Vietnam it is 
important to monitor the rate of TDRMs on a regular basis.  
6.4 PHYLOGENETIC RELATIONSHIPS AND TMRCA CALCULATIONS 
Previous studies of the CRF01_AE epidemiology in Vietnam have shown that HIV was first 
introduced in the southern part of the country and by 1993 over 950 infections had been 
diagnosed in Vietnam, of which only three cases were found in the north [195]. The 
introduction of HIV-1 CRF01_AE in Vietnam has been estimated to have occurred at least a 
decade prior to the first detections of clinical cases and by the late 1980’s the disease was 
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believed to have been spreading among IDUs in South Vietnam and thereafter to IDUs in 
the northern part of the country around 1993-1994 [196]. Our results date the tMRCA of the 
clade currently spreading through sexual and intravenous transmission in North Vietnam a 
few years prior to this, around 1990. This clade, ‘Vietnam large clade’ includes samples 
from Ha Long, Uong Bi, Dong Trieu and Yen Hung from the current study (n=60), as well 
as sequences from Hai Phong [36], Bac Giang and Hai Duong [196] also located in the 
coastal North-Eastern part of Vietnam (n=22), plus a number of intermixed strains from 
China and the Czech Republic (n=13). The tMRCA for the North Vietnam cluster 
calculated by Liao et al was based on a smaller number of samples (8 Vietnamese + 2 
Chinese samples), which explains the discrepancy between these studies. Indeed, six of 
these strains were included in the current study and the tMRCA of these strains fell around 
1993-1994 (Figure 21, Vietnamese strains sampled 1998). It is therefore likely that larger 
sampling rather than methodological differences accounts for the different time estimates, 
and that HIV first spread to Northern Vietnam around 1990 or earlier.  
The ‘Vietnam small clade’ has an estimated tMRCA around 1997, but since the number of 
strains is small it is difficult to say if they represent an emerging cluster in the north or if the 
three infections were unrelated. BLAST searches confirmed that these strains were more 
similar to samples from southern Vietnam (Ho Chi Minh City, An Giang) and Thailand than 
to North Vietnamese and Chinese CRF01_AE strains. One of these samples originated from 
a truck driver, who had travelled widely throughout Vietnam in his job, and the other two 
samples came from women who were/had been married to drivers. It is therefore possible 
that these strains were independently introduced from the southern part of the country. None 
of these genetically divergent strains carried TDRMs.  
The Vietnamese samples analyzed in this study originated from four clinics in the Quang 
Ninh province in Northeastern Vietnam, near the border to China. These clinics are all 
located within a radius of approximately 35 km, and no local clustering was found for the 
respective sites. Twenty-nine samples originated from patients with a history of intravenous 
drug use, 27 individuals were infected through sexual transmission and the mode of 
transmission for the remaining seven patients was unknown. Samples from patients with 
different modes of infection were completely intermixed in the phylogeny (Figure 21), 
indicating that HIV-transmission frequently occurs between intravenous drug users and non-
drug users in northern Vietnam. 
 65 
7 METHODOLOGICAL CONSIDERATIONS 
This is the first cluster randomized controlled trial on HIV conducted in a rural setting in 
Vietnam, therefore we had limitations and constraints in logistics, in recruiting patients, 
collecting data and analysis. The recruitment took two years instead of the 10 months that 
we had originally planned.  
Our studies were conducted in one province hence the results may not be representative of 
the whole picture in Vietnam. On enrollment, there were many patients who were already 
very sick with severely immuno-suppressed, having low CD4 and being clinical stage 4, 
therefore the reported mortality might not represent the mortality of the whole of PLHIV in 
the region. Also, for that reason, the impact of peer support on mortality might not have 
been fully evaluated.  
Six percent of patients who were ART-non-naïve could present a selection bias. Patients in 
both groups may receive other community-based supports that might be a “contamination”. 
In addition, patients in the intervention group could meet and share adherence experiences 
with patients in the control group at the clinic (i.e, there were 2 couples of whom the men in 
the intervention group married women in control group). In this study, resistance testing has 
not been applicable for those who developed virologic failure therefore we did not know the 
real pattern of drug resistance mutations in the cohort. As the constraint of budget is a 
barrier to extending the patient’s follow-up, so the termination of data collection at the 24-
month-follow-up may not be enough to clearly see the impact of adherence support.  
Another limitation of this study is that TDR may not reflect the most recent trends in 
transmission because the majority of the patients (84%) had advanced immunodeficiency 
(CD4<200) and had most likely been infected for several years at the time of sampling. 
Consistent with this assumption, the phylogenetic tree revealed that the tMRCA of the most 
closely related sequences often occurred around 7-12 years ago. Thus, late testing appears to 






 Peer support had no impact on virologic failure and CD4 trends, on mortality after 
24 months of follow-up.  
 The majority of patients presented late to ART; consequently most deaths occurred 
early, within six months of ART initiation. 
 TB was the most common cause of death.  
 Low virologic failure and high retention in care rates were found. 
 High VL at baseline was a predictive factor for virologic failure, CD4 trends and 
mortality.  
 Transmitted drug resistance rate should be regularly monitored prospectively in 
Vietnam.  
 There was a strong correlation between ExaVir Load and PCR Tapman VL, with 
high agreement, high sensitivity and specificity found. 
 Good field performance of ExaVir Load and feasibility to implement routine VL 




9 REFLECTIONS  
We found no difference between the intervention and control groups in this study in relation 
to virologic failure rates, time to failure, CD4 trends and mortality. By describing the 
implementation of ART programs in Quang Ninh we may conclude that if the OPC 
provides adequate adherence counseling and preparedness for pre-ART training, as well as 
monitoring routinely patients clinically, immunologically and virologically, the adherence 
by peer support may not need to be enhanced. Hence our outcomes suggest there is more 
benefit in investing a good clinical care the clinic rather than in community support. 
However, peer support could improve the quality of life so we suggest that if other 
parameters are accounted for, there is a benefit to be found with the presence of peer support 
and it may have long-term impacts on treatment effectiveness that may not be assessable 
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Phiếu theo dõi tuân thủ điều trị dành cho nhân viên hỗ trợ 
(ART adherence form for peer supporter) 
Lần thăm thứ ……. )                              gà :   th ng   n m 20                    
                                 (Visit number    )                         (Date  ../   ./ 20  . ) 
Mã bệnh nhân: (Patient ID)       
1. Họ tên người hỗ trợ bệnh nhân trong gia đình: …………………………………………………2. uan hệ   i bệnh nhân   : ……..…………… 
    Name of peer supporter                                                                                                            Relation to patient 
3. Đến thăm theo hẹn:                O 1. Đúng            O 2. Sai. (Lý do cụ thể: ………………………………………………………………………) 
Is this a scheduled visit?  Yes  No   (Reasons) 
4. B n c  s t  h ng? O1. Không.    O2.     (    nhiệt đ  nếu c  s t: ……………oC) 
Do you have fever            No    Yes    (Temp:________oC) 
5. ân n ng: …......kg. 
Weight 
 . Trong tuần  ua, mức đ  ho t đ ng cơ th  c a b n như thế n o? 
     Functional status 
    O 1. Bình thường             O 2. Khó khăn khi đi lại                          O 3. Nằm liệt giường.  Số ngày: …....... 
        Normal                        Have symptoms but can work as normal                      Bedbound. Da s  . 
7. Trong tuần  ua, mức đ  b n cảm thấy h i   ng   i cu c s ng như thế n o? 
    Are you currently satisfied with your life? 
O 1. Không chút  nào       O 2. Một chút          O 3. Bình thường        O 4. Hài lòng        O5. Rất hài lòng         O 9.  Không biết 
   Not at all                              a little                     normal                       satisfied                    very satisfied            unknown 
8. Trong tuần  ua, b n c  những dấu hiệu/ triệu chứng n o:  
    What symptoms did you have in last week? 
O 1. Không có triệu ch ng           O 2. Có triệu ch ng                              O 9. Không biết/ không trả lời       
        No symptom                          Yes, have some symptoms Unknown/ Don’t answer 
(ghi cụ th  các triệu chứng/dấu hiệu nếu c ): specify symptoms/signs............………………………………………..…… 
……………………………………………………………………………………………………………………………….. 
 . T   ần  hám trư c b n c  được ch n đoán    điều tr  bệnh  ao, các bệnh nhi m trùng cơ h i hay bệnh gì  hác  h ng?  
Were you diagnosed or got  treatment for TB, OIs or other diseases in previous medical examinations? 
O 1. Không                           O 2. Có                                                         O 9. Không biết/ không trả lời     
        No                           Yes   Unknown/ Don’t answer 
(Nếu c , ghi tên bệnh đã được ch n  đoán):.Specify.........................................…................................................... 
1 . B n đang u ng thu c  hác đ  n o:    O 1. 1a;                         O 2. 1b;                        O 3. 1c;                        O 4. 1d; 
Which ARV regimen are you taking?  
 hi  r  đầy đ  tên thu c:..1.....................................+ .2.................................................+ 3................................................. 
Specif  ARV’s names 
11. B n u ng mỗi  ần bao nhiêu  iên thu c A  ?  
What is your schedule for taking ARV tablets/pills every day? 
O 1. Sáng: …….viên                   O 2. Tối: ……viên                     O 3. Đêm: …… viên                          O 9. Không biết 
 Morning: ..... tabs                        Evening: ...... tabs                  Night: ...... tabs                       Unknown 
12. B n thường u ng thu c A     o mấy giờ? 
What time usually do you take ARVs? 
O 1. Sáng: ……... h ……...            O 2. Tối: ……. h ……...        O 3. Đêm: …….. .h ……...          9. Không biết  
         Morning: ..... h..........    Evening: ...... h..........                          Night: ...... h........                        Unknown 
13.   biện  há  n o gi   b n đ  u ng thu c đ ng giờ? (   thể chọn nhi u khả n ng- multilple choices) 
Any methods help you to take medicines in time?  
 1. Đ t chuông điện thoại di động              2. Đ t chuông đ ng h  báo th c              3. D ng hộp nh c thuốc          4. Có người nh c (Người đó là: .................) 
      Set a phone alarm                Set a o’clock alarm                            Pill box                           A family reminder .............  
 5. D ng l ch nh c thuốc                            6. Nhìn đ ng h /TV                                  9. Khác: .............................. 
       Calendar                                 Watches/TV                                              Others 
14. Trong 4 ngày qua, b n c  bỏ u ng thu c A    ần n o  h ng? O 2. Không (chu ển c u 15)           O 1. Có (xem bảng dư i)  
Did you miss dose of ARV in 4 day ago?                                    No. Go to 15                       Yes. View below table         




2 hôm trư c 
2 day ago 
3 hôm trư c 
3 day ago 
4 hôm trư c 
4 day ago 
 hi ch  
Notes 
Sáng- Morning O1. O 4. O 7. O 10. 
 Tối -Evening O2. O 5. O 8. O 11. 
Đêm -Night O3. O 6. O 9.  O 12. 
APPENDIX 1  
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15. Đếm s  thu c A   c n   i:      O1. Tên thuốc (….............................................................., còn ....................viên; ) 
Pill count                                      name of drug                                                                         remaining     pills 
                                                    O2. Tên thuốc:…......................................................................., còn…................ viên;   
                                                            name of drug                                                                         remaining     pills 
                                                      O3. Tên thuốc:…......................................................................., còn…................ viên;    
                                                            name of drug                                                                         remaining     pills           
1 . T i sao b n  h ng u ng thu c A   trong tuần  ua? (Bỏ              ế   ệ              ủ      ) 
Why did you miss taking the doses of ARV for last week? 
          1. Quên                               6. Sợ uống quá nhiều thuốc                     11. Không tin vào tác dụng của thuốc 
               Forgot  Afraid of taking too many pills              Do not trust 
            2  Bận                                  7. Sợ người khác biết                               12. Bu n nên không uống thuốc   
               Busy  Afraid of being seen by somebody              Depressed/sad                                                                                       
          3..Có tác dụng phụ             8. Không có tiền ăn và chữa  bệnh         13. Bán/chia thuốc cho người khác    
                Side effects Financial problem, nothing to eat              Sell/Share ARV with others. 
          4. Cảm thấy khoẻ nên ngừng thuốc        9. Hết thuốc                          14. Lý do khác. Nêu cụ thể……………… 
               Feels better then discontinue                 Run out of ARVs             Other................................................. 
          5.Ốm n ng hơn                                   10. Không đi lấy thuốc được                                 99.  Không trá lời  
               Feels worse              Difficulties in transportation to refill ARV           Don’t answer 
17. Trong 4 ngày qua, b n c   uên u ng thu c A   sai giờ (   p        l  ) không: 
Did you late to take ARV in 4 day ago (over 30 min.)? 
O1. Không               O2. Có                          O 9. Không biết, không trả lời                  Nếu có: Số l n uống sai giờ:…................. 
       No         Yes                 Unknown/ Don’t answer  If yes, ................ times 
18. Nh n  ét/đánh giá chung  ề  iệc tuân th  điều tr  c a bệnh nhân:  
Evaluation on adhrence 
             O1. Tốt                                     O2. Trung bình                                   O 3. K m. 
                       Good               Moderate/not good               Poor 
1 . Kế ho ch hỗ trợ bệnh nhân nếu họ tuân th   h ng t t:  
Plan to support patient and give the solutions if the adherence is not good 
.….………………………………………………………………………………………………………………………………………………………………..……..... 
2 . Lần thăm  ế tiế :  ngày..................tháng............. năm 20................  







PHIẾU ĐÁNH IÁ TUÂN THỦ ĐIỀU T Ị 
ADHERENCE ASSESSMENT FORM (filled by health staff every 3 months) 
(Do nh n viên   tế hỏi bệnh nh n 3 th ng 1 lần) 
A. Thông tin chung: (Genenal information) 
* Mã bệnh nhân:          
Patient ID 
* Người hỗ trợ đi c ng bệnh nhân là: 
Family member supporter  
 1. Bố ho c m  bệnh nhân 
Father or mother 
 2. Vợ ho c ch ng bệnh nhân 
Husband/wife 
 3. Thành viên khác trong gia đình__________.       
Others member in family 
Specify : __________________________ 
 4. Bạn của bệnh nhân 
Friends 
 5. Người khác. Ghi rõ:__________________ 
Other relatives 
 6. Đi một mình 
No one 
* Người phỏng vấn:___________________ 
Interviewer 
* Ngày phỏng vấn: - - 20  
(ngày – tháng – năm) 
Date of inteview 
(day – month – year) 
* Đ a điểm phỏng vấn:  
Place of interview 
 1. BV T nh QN (Ha Long CDC clinic) 
 2.BV Uông  B ; (Uong Bi Clinic) 
 3.PK Yên Hưng; (Yen Hung clinic) 
 4.TTYT Hạ Long (Ha Long Health Center) 
* H  tên bệnh nhân: _____________________ 
Patient name  
* Gi i t nh:  1. Nam            2. Nữ 
Gender:               Male           Female 
* Đ a ch  : ___________________________ 
                   ___________________________ 
Address 
 Ngày sinh: - -19   
 DOB (day – month – year) 
   
B. Th ng tin  ề  hác đ  điều tr      iều  ượng  Regimen and dose infomation 
B1. B n đang u ng thu c A   theo  hác đ  n o?) 
What ARV regimen are you using? 
  1. Phác đ  1a (d4T + 3TC + NVP ) Regimen 1a   
  2. Phác đ  1b ( d4T + 3TC + EFV)  Regimen 1b   
  3. Phác đ  1c ( AZT + 3TC + NVP) Regimen 1c   
  4. Phác đ  1d ( AZT + 3TC + EFV) Regimen 1d   
  5. Khác (Ghi rõ        .      . ) 
Other. Spectify: ______________________ 
  6. Không biết Unknown 
 
B2. B n u ng bao nhiêu  iên thu c A   mỗi  ần? 
How many pills do you take each time?    
 1. Sáng: _____ viên  
Morning :____ pills              
 2. Tối  : _____ viên 
Evening :_____ tablet                    











C. Phần dư i đây hỏi  ề các thu c A   m  b n đã dùng trong 4 ngày qua. 
(Questions below about taking drung for last 4 days) 
( Hã  đ nh dấu vào c c ô vuông theo sự trả lời của bệnh nh n.) (Tick on the box) 
 1. B n  h ng u ng thu c A   những   c n o? 
 (When did you forget to take ARV pills ?) 
Tên thuốc ARV 
ARV 
Name of ARV 
Hôm qua 
Yesterday 
2 hôm trư c 
2 day ago 
3 hôm trư c 
3 day ago 
4 hôm trư c 
4 day ago 
  3 trong 1    
3 in 1 
 1. Sáng  
(Morning)                                                                
 2. Tối 
(Evening) 
 1. Sáng  
(Morning)                                       
 2. Tối 
(Evening) 
 1. Sáng  
(Morning)                                         
 2. Tối 
(Evening) 
 1. Sáng  
(Morning)                                       




 1. Sáng 
(Morning)                                                                
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                       
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                         
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                       




 1. Sáng 
(Morning)                                                                
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                       
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                         
 2. Tối 
(Evening) 
 1. Sáng 
(Morning)                                       





 1. Sáng 
(Morning)                                                                
 2. Tối 
(Evening) 
 3. Đêm 
(Night) 
 1. Sáng 
(Morning)                                       
 2. Tối 
(Evening) 
 3. Đêm 
(Night) 
 1. Sáng 
(Morning)                                         
 2. Tối 
(Evening) 
 3. Đêm 
(Night) 
 1. Sáng 
(Morning)                                       
 2. Tối 
(Evening) 
 3. Đêm 
(Night) 
 Không bỏ liều nào 
Don’t forget/miss an  doses 
 2.    bao nhiêu ng y b n hoàn toàn  h ng u ng thu c? (How many days you did not take any doses) 
  1. Một ngày 1 day 
  2. Hai ngày 2 day 
  3. Ba ngày 3 day 
  4. Bốn ngày 4 day 
  5. Không ngày nào Not at all 
C3. Trong 4 ngày qua, b n u ng thu c A   ch m giờ (3   h t tr   ên) bao nhiêu  ần:_______ 
For last 4 days, how many time did yod you delay in taking drugs? 
 
B3. B n thường u ng thu c A     o mấy giờ? 
What time do you often take ARV pills?    
 1. Sáng :_________ h _______ 
Morning :                     
 2. Tối   :_________ h _______  
Evening                  
 3. Đêm :_________ h _______     
Night                 
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C4. Trong 4 ngày qua b n tuân th    ch u ng thu c như thế n o?  
For last 4 days, what do you think about your adherence? 
  1. Tuân thủ hoàn toàn (completely) 
  2. Tuân thủ h u hết số l n (I took most of doses) 
  3. Tuân thủ một nửa số l n (I took half of doses) 
  4. Tuân thủ một vài l n (I took some doses) 
  5. Hoàn toàn không tuân thủ (I did not take any dose) 
 5. Lần cu i cùng b n  uên  h ng u ng thu c     hi n o? ( hỉ chọn một khả n ng)  
When did you forget to take the last dose?  
  1. Tu n trư c  Last week 
  2. Trong khoảng 2 tu n trư c  2 week ago 
  3. Trong khoảng 3-4 tu n trư c  3-4 week ago 
  4. Không bao giờ quên uống thuốc  ( hu ển c u 11)  ever forget. (Go to 11) 
C6. B n c  u ng thu c A   theo chỉ dẫn c a bác sĩ  h ng   
(v  dụ như “uống trong khi ăn” ho c “uống lúc đói”, “uống v i nhiều nư c” ho c “uống trư c khi đi ngủ”) ? 
Do you follow the instructions of doctor regarding adherence: i.e : taking ARVs with food, or with empty 
stomach, large amount of water or before going to sleep?  
 1. Có   2. Không (chuyển câu C8). 
 Yes No (go to C8) 
 7. B n tuân th  theo các chỉ dẫn đ  c a bác sĩ   mức đ  n o? 
  1. Tuân thủ hoàn toàn (completely) 
  2. Tuân thủ h u hết số l n (almost completely) 
  3. Tuân thủ một nửa số l n (about half) 
  4. Tuân thủ một vài l n (a little) 
  5. Hoàn tòan không tuân thủ (not at all) 
 8. B n c   uên u ng thu c   o ng y thứ 7     h  nh t tuần   a  ua  h ng?  
(Did you forget to take drug on the last weekend?) 
 1. Có     2. Không   




D. Dư i đây    m t danh sách các  ý do m  b n c  th   uên trong tháng  ua: (list the reasons for missing 
the doses below) 
Lí do  h ng u ng thu c 
(Đ nh dấu vào ô phù hợp) 
Reason forget ARV 
(Check in right box) 
Tần suất (Khoanh vào số phù hợp) 












  1. Quên Forget 0 1 2 3 
  2. Bận Busy            0 1 2 3 
  3. Do thuốc gây ra tác dụng phụ  
            Side effects     
0 1 2 3 
  4. Cảm thấy khoẻ hơn nên ngừng thuốc 
          Feel better then stop   
0 1 2 3 
  5. Uống vào nôn ra  Vomiting 0 1 2 3 
  6. Ốm n ng hơn  Getting worse             0 1 2 3 
  7. Sợ uống quá nhiều viên thuốc  
          Too many pills 
0 1 2 3 
  8. Sợ người khác biết, nhìn thấy       
          Fear of disclosure to other people               
0 1 2 3 
  9. Không có tiền ăn và chữa bệnh 
          No money for foods and treatment                                                                                                                                          
0 1 2 3 
  10. Hết thuốc không k p đi lấy  
        Did not come to clinic ontime                            
0 1 2 3 
  11. Nhà xa không đi lấy thuốc được   
       Living to far from the clinic       
0 1 2 3 
  12. Không tin vào tác dụng của thuốc 
       Don’t trust on ARVs effects 
0 1 2 3 
  13. Bu n chán nên không uống thuốc   
       Depressed/sad                                                                                                                 
0 1 2 3 
  14. Bán/chia thuốc cho người khác 
       Sell/sharing ARVs to others 
0 1 2 3 
  15. Lý do khác (ghi rõ______________) 
Other (Spectify:_____________________) 
0 1 2 3 
  16. Không trá lời   No answer 0 1 2 3 
E. Đếm s   iên thu c c n   i m  bệnh nhân mang đến (Pill count) 
E1. Bạn có mang số thuốc còn lại đến không?  
Do you bring the remaining of ARVs? 
 1. Có Yes  
                2. Không→ Chuyển sang câu E3. No. Go to E3 
E2. Đếm số thuốc còn lại và so sánh v i số thuốc đã uống theo qui đ nh 
Count the pills remaining, compared to the pills which were designated by doctors 
   1. Đủ số thuốc  (exactly enough) 
  2. Thừa thuốc, (Ghi rõ số viên thuốc thừa:____________________)  (redundancy) 
  3. Thiếu thuốc, (Ghi rõ số viên thuốc thiếu:___________________) (lack of ARVs) 
E3. Đánh giá mức đ  tuân th :  Evaluation of adherence 
* Số l n không uống thuốc:_________________ Number of missed doses 
* M c độ tuân thủ của người bệnh: Level of adherence 
  1. Tuân thủ tốt  (quên <4 l n/tháng) 
Good adherence (missed < 4 doses/month) 
  2. Tuân thủ khá ( quên 4- 8 l n/tháng) 
Moderate adherence (missed 4-8 doses/month) 
  3. Tuân thủ k m ( quên  8 l n/tháng) 
(Poor adherence) (missed > 8 doses/month) 
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F. Hãy     ề những triệu chứng b n c  trong m t tháng   a  ua    mức đ  ảnh hư ng đến cu c s ng 
c a b n? (Tell me if you have any side effects - Tick the boxes below) 
B n c  các triệu chứng sau đây  h ng? 
((Đ nh dấu vào ô vuông bên cạnh, nếu c , và  hỏi v  
mức độ ảnh hưởng) 
Do you have any symptoms as listed below: 
Mức đ  ảnh hư ng(Khoanh vào số phù hợp) 













tr m tr ng 
Very much 
  1. Mệt mỏi fatigue 0 1 2 3 
  2. Sốt fever 0 1 2 3 
  3. Cảm giác r t run ho c vã m  hôi           
chills/sweating 
0 1 2 3 
  4. Chóng m t Dizziness 0 1 2 3 
  5. Đau nh c, tê bì ở 2 bàn chân, bàn tay numbness 
in fingers or toes 
0 1 2 3 
  6. Giảm tr  nh  dementia 0 1 2 3 
  7. Bu n nôn/ nôn nausea/ vomiting 0 1 2 3 
  8. Ỉa chảy diarrhea 0 1 2 3 
  9. Bu n chán Sad/depressed 0 1 2 3 
  10. H i hộp, lo l ng Anxiety 0 1 2 3 
  11. Khó ngủ, ngủ không yên giấc  
           sleeping disturbance 
0 1 2 3 
  12. Ngủ g p ác mộng Nightmare 0 1 2 3 
  13. Phát ban, ng a, khô da rash/itching 0 1 2 3 
  14. Ho, khó thở cough/ dyspnea 0 1 2 3 
  15. Đau đ u headache 0 1 2 3 
  16. Chán ăn, thay đổi khẩu v  lost of appetite 0 1 2 3 
  17. Đ y bụng, đau v ng thượng v  stomach ache 0 1 2 3 
  18. Đau cơ, kh p joint pain 0 1 2 3 
  19. Giảm quan hệ tình dục lost of sexual desire 0 1 2 3 
  20.Thay đổi về ngoại hình (chân tay g y guộc hơn 
trư c, thái dương và má tóp lại) lipoatrophy 
0 1 2 3 
  21. Sút cân weight lost 0 1 2 3 
  22. Rụng tóc hair-loss 0 1 2 3 
  23. Vàng da, vàng m t jaundice 0 1 2 3 
  24. Sưng hạch lymphadenopathy 0 1 2 3 
  25. M t nhìn mờ blurred eyes 0 1 2 3 
 . 26. Có ý tưởng t  tử thoughts of suicide 0 1 2 3 
 27. Không g p phải bất c  tình huống nào nothing  
 








PHIẾU XÁ  ĐỊNH N UYÊN NHÂN TỬ  ON  
(VERBAL AUTOPSY QUESTIONNAIRE) 
1 Người thu thập thông tin 
Data collector) 
 
2 Ngày phỏng vấn 
(Date of interview) 
 ___ ___ / ___ ___ / ___ ___ ___ ___ 
   Date        Month     Year 
 
3 Thời gian phỏng vấn  
(Duration of interview) 
 
PHẦN 1: THÔNG TIN VỀ NGƯỜI ĐÃ MẤT ( iề   á    ô    i  sẵ   ó) De e se ’s i f     i   
1.1 Mã bệnh nhân (Patient ID) 
 
1.2 
H  và tên người mất  
Name of the deceased) 
O 1. Nam (Male) 
1.3 Gi i t nh Sex) O 2. Nữ (Female) 
1.4 Xã/phường (Commune)  
1.5 Huyện (District)  
BẮT ĐẦU PHỎN   ẤN: 
Hư ng dẫn cho điều tra viên: Điều tra viên t  gi i thiệu và giải th ch mục đ ch phỏng vấn. Đề ngh  được g p cha/m  người đã mất 
ho c người chăm sóc ch nh cho người mất. Nếu không g p được người chăm sóc ch nh thì xin h n ngày khác để quay lại.  
(Guide to inteviewers: Inteviewers introduce about themselves and explain about the purposes of the data collection. 
Ask for meeting father/mother or caretaker of the deceased. Make another appointment in case you will not be able to 
arrange a meeting with caretaker).  
“Tôi tên là .. , là c n bộ của dự  n DOTARV. Tôi được biết gia đình mình c  người mới mất và tôi xin được ch n thành chia buồn 
với gia đình.  Với mục đích n ng cao sức khoẻ cho cộng đồng, chúng tôi đang làm nhiệm vụ thu thập c c thông tin liên quan đến tình 
hình tử vong.  hính vì vậ , tôi xin phép được đến th m gia đình và tìm hiểu v  tình hình sức khoẻ và bệnh tật mà người mất đã mắc để 
tìm hiểu ngu ên nh n tử vong. Tôi xin đảm bảo rằng những thông tin thu thập được chỉ dành cho mục đích nghiên cứu và n ng cao 
sức khoẻ cộng đồng.” 
(Hello. My name is ____________ and I am working with DOTARV project. We are currently collecting information from the family 
to verify the causes of death in the community. We would very much appreciate your participation in this interview. We want to ask 
you about the circumstances leading to the death of the deceased. Whatever information you provide will be kept strictly confidential. 
No information identifying you or the deceased will ever be released to anyone outside of this information-collection 
activity.Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. 
However, we hope that you will participate in this survey since the results will help the government improve services for people) 
  
PHẦN  : THÔNG TIN VỀ NGƯỜI TRẢ LỜI   
Part 3: General information about the interviewee  
3.1 
Gi i t nh (Sex) 
 
O   1. Nam (male) 
O   2. Nữ (female) 
3.2 Tuổi (Age)   
 
3.3 
Quan hệ v i người mất:  
(What is your relationship to the deceased?) 
(Ch  ch n 1 thông tin)  
(Choose only one answer) 
O   1. Bố/m  (father/mother) 
O   2. Ông/bà (grandfather/grandmother) 
O   3. Vợ/Ch ng (spouse) 
O   4. Anh/ch /em (sibling) 
O   5. Con (child) 
O   (other relative, specify)  
  
PHẦN  : THÔNG TIN CHUNG VỀ NGƯỜI MẤT  
 (Part 4: General information about the deceased)  
4.1 
H  tên người mất  
(What was the name of the deceased?) 
  
4.2 
Ngày, tháng, năm sinh  
(When was the deceased born?) 
O Dương l ch (solar calendar)  
O Âm l ch (lunar calendar)       
4.3 Gi i t nh (Gender?) 
O   1. Nam (Male) 





Nơi mất (Where did s/he die?) 
(ch  ch n 1) (Choose only one) 
O   1. Tại nhà (At home) 
O   2. Tại cơ sở y tế công (Government clinic) 
O   3. Tại cơ sở y tế tư (Private clinic) 
O   4. Trên đường đến cơ sở y tế (On the way) 
O   9. Khác, ghi rõ  (Other, specify) 
4.5 Ngày tháng năm mất (When did s/he die?) 
O Dương l ch (solar calendar)  
O Âm l ch  (lunar calendar)      
4.6 
Tình trạng hôn nhân trư c khi mất 
(What was her/his marital status?) 
(ch  ch n 1) (Choose only one) 
O   1. Chưa lập gia đình (Never married) 
O   2. Đã có gia đình (Married/living with a partner?) 
O   3. Đã ly thân  (Separated) 
O   4. Đã ly hôn (Divorced) 
O   5. Góa bụa (Widowed) 
4.7 
Trình độ h c vấn 
(What was the highest level of fomal education the 
deceased attended) 
(ch  ch n 1) (Choose only one) 
O   1. M  chữ (illiterated) 
O   2. Cấp 1 (Primary school) 
O   3. Cấp 2 (Secondary school) 
O   4. Cấp 3 (Junior high school) 
O   5. Trên cấp 3 (University or higher) 
4.8 
Nghề nghiệp ch nh (What was her/his occupation, that is, 
What kind of work did s/he mainly do) 
(ch  ch n 1) (Choose only one) 
O   1. Làm ruộng (farmer)  
O   2. Cán bộ viên ch c (Government staff) 
O   3. Công nhân (Worker) 
O   4. Về hưu (Retired) 
O   5. Nội trợ (Housewife) 
O   6. H c sinh/ Sinh viên (Pupil/student) 
O   9. Khác, ghi rõ (Other, specific)  
  PHẦN 5: TAI NẠN / THƯƠNG TÍCH   (Part 5: Accident/Injuries)   
5.1 
    hải (   ời ấ ) mất do tai n n  h ng? 
(Did she/he suffer from injured or accident that led to 
her/his death?) 
O   1. Có phải (Yes) 
O 
  2. Không phải (No) 
  
 huy n 
 hần    
S i   art  ↓ O 
  9. Không biết/ Không trả lời 
 (Don’t know/ o answer) 
5.2 
Nếu có, do nguyên nhân gì? 
(What kind of injured or accident did the deceased suffer 
from?) 
O 
1. Thương tích do tai nạn giao thông  
(Traffic accident) 
O   2. Bị ngã (Falling) 
O   3. Bị chết đuối (Drowning)  
O   4. Bị ngộ độc (Poisoning) 
O 
  5. Bị một loài vật c  nọc độc cắn (rắn) ha  đốt (ong)  
Bite (Snake) or Sting (Insect) 
O   6. Bị bỏng (Burning) 
O   7. Tự tử, tự gây ra (Suicide) 
O   8. Bị s t hại, đ nh nhau (Assault,Fighting) 
O   9. Bị điện giật (Electronic shock) 
O    
O 
  999. Không biết/ Không trả lời 
(Don’t know/  o answer) 
5.3 
( gười mất) có uống rượu trư c khi g p tai nạn không? 
(Did s/he drink alcohol before the accident?) 
O   1. Có uống (Yes) 
O 
  2. Không uống (No) 
  





  9. Không biết/ Không trả lời 
 (Don’t know/  o answer) 
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5.4 
Từ lúc uống ruợu cho đến lúc g p tai nạn là bao lâu? 
(How long before death did s/he stop drinking?) 
O   1. Dư i một tiếng (Less than one hour) 
O   2. Từ 1 - 6 tiếng (From one to six hours) 
O   3. Hơn 6 tiếng (More than six hours) 
O 
  9. Không biết/ Không trả lời  
(Don’t know/  o answer) 
5.5 
Sau khi b  tai nạn thương t ch bao lâu thì mất?  
(How long did it take from accident to death?) 
O Giờ (Time)    
O Ngày (Date)  
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 




Trong đợt ốm trư c khi mất, (người mất) có đi khám 
chữa bệnh ở đâu không? 
(Did the deceasec receive treatment during the illness 
that led to death?) 
O   1. Có (Yes) 
O 
  2. Không (No) 
  
 huy n 
 hần  .8 ↓ 
Skip 6.8↓ O 
  9. Không biết/ Không trả lời 
 (Don’t know/  o answer) 
6.2 
Nếu có, (người mất) được khám chữa bệnh ở những đâu? 
(If Yes, please tell me at which of following 
places/facilities s/he received treatment during the illness 
that led to death?) 
 
1. Thầ  lang/đông   
(Traditional doctor/medicine) 
   2. Thầ  cúng hoặc cha xứ (monk or vicar) 
   3. TYT xã/phường (primar  health care) 
   4. Bệnh viện quận/hu ện (District hospital) 
   5. Bệnh viện Trung ương (Central hospital) 
   6. Hộ sinh (midwife center) 
   7. B c sĩ tư nh n (Private clinic) 
 
  8. Nhà thuốc, người b n thuốc, ở cửa hàng và ở chợ 
(Pharmacy, Drug seller, store and market) 
   9.  ơi kh c (Other) 
   10. Họ hàng, bạn bè (Relatives, friends) 
 
  99. Không biết/ Không trả lời 
 (Don’t know/  o answer) 
6.3 
Ghi lại tên và đ a ch  của bệnh viện/ trung tâm  y tế mà 
( gười mất) từng được chăm sóc trư c khi mất: 
(Record name and address of hospital/medical center 




Ông/bà còn giữ giấy tờ liên quan đến việc khám chữa 
bệnh của ( gười mất) không? 
(Do you have any medical document of the deceased?) 
(Do you have medical record of the deceased?) 
O   1. Có (Yes) 
O 
  2. Không (No) 
  
Chuyển 6.8 ↓ 
Skip 6.8↓  
O 
  9. Không biết/ Không trả lời 
 (Don’t know/  o answer) 
 
6.5 
Tôi có thể xem giấy tờ đó được không? 
(May I see his/her medical record?) 
O   1. Có, cho xem giấy tờ (Yes) 
O 
  2. Không (No) 
  
Chuyển 6.8 ↓ 
Skip 6.8↓   
O 
  9. Không biết/ Không trả lời 




Ghi lại thời gian đợt khám chữa bệnh cuối c ng của 
người mất được ghi ch p trong giấy tờ 
(Record the time of treatment during the illness that led 
to death?) 
 
 (The last time) 
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6.7 
Ch p lại những ghi ch p trong giấy tờ về l n khám cuối 
  (Record the information about the last visiting) 
 - Tiền sử (History) 
 - Chẩn đoán (Diagnosis) 
 - Các x t nghiệm (Laboratories) 








Gia đình đã nhận "Giấy ch ng tử" của ( gười mất) 
chưa? 
(Do you have a death certificate for the deceased)? 
O   1. R i (Yes)   
O   2. Chưa (Not yet) 
Chuyển ph n 7 ↓ 
Skip 7 ↓ O 
  9. Không biết/ Không trả lời 
(Don’t know/  o answer) 
6.9 
Tôi có thể xem giấy ch ng tử được không? 
May I see the death certificate? 
O   1. R i (Yes)   
O   2. Chưa (No) 
Chuyển ph n 7 ↓ 
Skip 7 ↓ O 
  9. Không biết/ Không trả lời 
(Don’t know/  o answer) 
6.10 
Ghi lại nguyên nhân gây tử vong theo giấy ch ng tử  




P    7: C    ỏi        ậ  xé /      sá   ủ   iề       i    
 (Part 7: Openned questions and observation of interviewers) 
  
Câu hỏi: Ông/bà có thể kể lại diễn biến, c c triệu chứng, hội chứng bệnh tật dẫn đến tử vong và qu  trình đi u trị của (người mất) 
được không?  
Đi u tra viên lưu ý: Để người trả lời kể v  diễn biến tình trạng tử vong theo lời kể của họ.  ên gợi ý: thế còn gì nữa không ạ? Phải 
đảm bảo là người trả lời đã kể hết c c thông tin. 
(Could you please tell me whole story about symptoms, signs, syndromes that led to death’s progress of patient? Note: Let the 
interviewee fell free to talk according to his/her own way. The interviewer can add some supporting question: Anything else? Make 






   
  
ĐT  tự  ác đ nh: Người mất   :  




1. Do Tai nạn thương t ch 
(Injury/accident)   
  
KẾT THÚ  PHỎN   ẤN 
(End of interview) 
O 
2. Không phải tai nạn 






P    8: Cá    iệ    ứ  /  ội   ứ    ệ    ủ   ợ           k i  ử      
Part 8: Symtoms and signs noted during the final  illness 
1 
Người mất) có b  sốt không? 
(Did s/he have a fever?) 
O 1. Có (Yes)  
O 2. Không (No) 
 huy n 2 ↓ (Skip 
2↓) O 
  9. Không biết/Không trả lời 
(Don’t know/ No answer) 
1.1 
Sốt có cao không? 
(Did s/he have high fever?) 
O 
1. Sốt nh   
(Mild fever) 




  2.Sốt trung bình 
(Medium fever) 
O 
  3. Sốt cao  
 (High fever) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
1.2 
Đợt sốt k o dài bao lâu? 
(For how long did s/he have a fever?) 
O   Số ngày (Days  
O 
  99. Không biết/Không trả lời   
(Don’t know/  o answer) 
1.3 
Sốt diễn ra như thế nào? 
(What was the characteristics of fever?) 
O   1. Liên tục (Continuous) 
O   2. Lúc có lúc không (On and off) 
O   3. Ch  vào ban đêm (At night) 
O 
  9. Không biết/Không trả lời 
(Don’t kn(ow/  o answer) 
1.4 
( gười mất) có chảy m  hôi khi sốt không? 
(Did s/he have a sweating at fever?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
2 
( gười mất) có nổi phát ban không? 
(Did s/he have any skin rash?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 3 ↓ 
Skip 3 ↓ O 
  9. Không  biết/Không trả lời 
(Don’t know/  o answer) 
2.1 
( gười mất) b  nổi phát ban bao nhiêu ngày? 
(For how long did s/he have the skin rash?) 
O    
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
2.2 
Phát ban nổi ở đâu?  
(Where is the skin rash located?) 
(có nhiều l a ch n) (multiple choose) 
   1. M t (Face) 
   2. Thân mình (Body) 
   3. T  chi (Extremities) 
   4. Toàn thân (whole body) 
   5. Chỗ khác, ghi rõ (other, specific)  
 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
3 
( gười mất) có những vết thương/ lở lo t không? 
(Did s/he have an ulcer, abscess, or sore anywhere on the 
body?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 4 ↓ 
Skip 4 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
3.1 
Vết thương/ vết lở lo t có d ch trong hay có mủ không? 
(Did the ulcers/abcess have pus/discharing?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
4 
( gười mất) có b  ng a không? 
(Did s/he have itching?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
5 
(Người mất) có b  ung nh t ở bàn chân không? 
(Did s/he have tumor/abcess on foot?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n   ↓ 
Skip 6 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
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5.1 
Nh t có chảy mủ không? 
(Did the abcess/tumor have discharging?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n   ↓ 
Skip 6 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/ No answer) 
5.2 
Nh t chảy mủ bao nhiêu ngày? 




  99. Không biết/Không trả lời 
(Don’t know/ No answer) 
6 
( gười mất) có b  cảm giác đau như kim châm ở bàn chân 
không? 
 
(Did s/he have numbness in the sole of feet?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
7 
Trong đợt ốm trư c khi mất, môi (người mất) có b  tái nhợt 
không? 
(Did his/her lips look very pale at final illness?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
8 
Trong vòng 3 tháng trư c khi mất (Người mất) có b  giảm 
cân không? 
(Did s/he lose weight three months before death?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n   ↓ 
Skip 9 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
8.1 
Giảm khoảng bao nhiêu cân? 
(How many kilos did s/he lose?) 
O    
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
9 
(Người mất) trông có xanh xao không? 
(Did s/he look pale?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
10 
( gười mất) có b  vàng m t không? 
(Did she have yellow discoloration of the eyes?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 11 ↓ 
Skip 11 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
10.1 
( gười mất) b  vàng m t trong bao lâu? 
(For how long did s/he have yellow discoloration of the 
eyes?) 
O   Số tháng (months)   
O   Số ngày (days)   
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
11 
(Người mất) có b  sưng/ph /nề m t cá chân không? 
(Was the swelling/edema on ankles?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 12 ↓ 
Skip 12 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
11.1 
( gười mất) b  sưng/ph /nề m t cá chân trong bao lâu? 
(For how long did s/he have the swelling/edema on the 
ankles?) 
O    
O    
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
12 
( gười mất) có b  sưng/ph /nề m t không? 
(Did she have swollen/edema on face?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 13 ↓ 
Skip 13↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
12.1 
( gười mất) b  sưng/ph /nề m t trong bao lâu? 
(For how long did s/he have swollen/edema on face?) 
O   Số tháng (months)  
O   Số ngày (days)   
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
13 
( gười mất) có b  sưng/ph /nề cả người không? 
(Did s/he have swollen on the whole body?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 14 ↓ 
Skip 14 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer)  
13.1 
( gười mất) b  sưng/ph  cả người trong bao lâu? 
(For how long did s/he have swollen/edema on the whole 
O   Số tháng (Months  




  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
14 
( gười mất) có b  nổi hạch ở cổ không? 
(Were the ganglion on the neck?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
15 
( gười mất) có b  nổi hạch ở nách không? 
(Were the ganglion on the armpit?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời (Don’t know/ No 
answer) 
16 
( gười mất) có b  nổi hạch ở b n không? 
(Were the ganglion on the groin?) 
O   1. Có (Yes) 
O   2. Không (No) 
O   9. Không biết/Không trả lời 
17 
( gười mất) có b  ho không? 
(Did s/he have cough?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 18 ↓ 
Skip 18 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
17.1 
( gười mất) b  ho trong bao lâu? 
For how long did s/he have cough? 
O    
O   Số ngày (days)   
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
17.2 
Ho có đờm không? 
Was the cough productive with sputum? 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
17.3 
( gười mất) có b  ho ra máu không? 
Did s/he cough out blood? 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
18 
( gười mất) có b  khó thở không? 
Did s/he have breathlessness? 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 1  ↓ 
Skip 19 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
18.1 
( gười mất) b  khó thở trong bao lâu? 
For how long did s/he have breathlessness? 
O   Số tháng (Months)   
O   Số ngày (Days)    
O   Số giờ (hours  
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
18.2 
( gười mất) b  khó thở liên tục hay ng t quãng? 
Did s/he have continous or on and off breathlessness? 
O   1. Liên tục (Continous) 
O   2. Ng t quãng (On and off) 
O 
  9. Không biết/Không trả lời  
(Don’t know/ No answer) 
18.3 
( gười mất) b  khó thở nhiều hơn ở tư thế nào? 
What kind of position s/he felt most difficult in 
breathing? 
   1. Tư thế nằm (l ing) 
   2. Tư thế ngồi (sitting) 
   3. Đi lại/ Hoặc lúc gắng sức (moving) 
   4. Không bị ảnh hưởng bởi tư thế (no) 
 
  9. Không biết/Không trả lời (Don’t know/  o 
answer) 
19 
( gười mất) có b  thở khò khè không? 
(Did s/he have wheezing?) 
(Diễn tả thở khò khè bằng hành động) 
(Discribe wheezing by action) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
20 
( gười mất) có b  đau ng c không? 
(Did s/he have chest pain?) 
O   1. Có (Yes) 
O   2. Không (No)  huy n 21 ↓ 
Skip 21 ↓ O   9. Không biết/Không trả lời 
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(Don’t know/  o answer) 
20.1 
Cơn đau ng c kéo dài bao lâu? 
(For how long did s/he have chest pain?) 
O   1. Dư i 30 phút (less than 30 minutes) 
O 
  2. Từ 30 phút cho t i 24 tiếng (from 30 minutes to 
one hour) 
O   3. Trên 24 tiếng (more than 24 hours) 
O 
  9. Không biết/Không trả lời  
(Don’t know/ No answer) 
20.2 
Cơn đau ng c có diễn ra trong lúc vận động không? 
(Did the chest pain occur during exercise?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
20.3 
Đau ở v  tr  nào của ng c? 
(Where was the chest pain located?) 
 
(Đọc từng lựa chọn ở bên theo thứ tự) 
   1. Phía ngực trên và giữa 
   2. Phía ngực dưới tr i  
   3. Phía tay trái 
    
 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
21 
( gười mất) có đi  a chảy hay phân nát nhiều hơn bình 
thường không? 
(Did s/he have diarrheoea?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 22 ↓ 
 Skip 22 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer)  
21.1 
( gười mất) b  đi  a chảy bao lâu trư c khi mất? 
(For how long did s/he have diarrhea before death?) 
O    
O 
  99. Không biết/Không trả lời (Don’t know/ No 
answer) 
22 
( gười mất) có b  táo bón không? 
(Did s/he have constipation?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
23 
Trong phân có máu không? 
(Was there blood in the stool?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 24 ↓ 
 Skip 24 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
23.1 
( gười mất) có b  đi ngoài ra máu cho t i lúc mất 
không? 
(At any time till death was there blood in the stool?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
24 
( gười mất) có b  b  tiểu (khó đi tiểu, ho c không đi tiểu 
được) không?  
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
25 
( gười mất) có b  nôn trong vòng một tu n trư c khi mất 
không? 
(Did s/he vomit within one week before death?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 26 ↓ 
Skip 26 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
25.1 
Nếu có, l n b  nôn cuối c ng trư c khi mất bao lâu? 
(If Yes, for how long did she have last vomit before death?) 
O   Số ngày  
O   Số giờ (hours)   
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
25.2 
( gười mất) có b  nôn ra máu không? 
(Did the vomiting look like bright red/blood red?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
25.3 
Chất lỏng nôn ra có màu đen không? 
(Did the vomiting look like coffee-colored fluid?) 
O   1. Có (Yes) 
O   2. Không (No) 
O   9. Không biết/Không trả lời 
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(Don’t know/  o answer) 
26 
( gười mất) có b  khó nuốt không? 
(Did s/he have dysphagia?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 27 ↓ 
 Skip 27 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
26.1 
Khó nuốt bao lâu trư c khi mất? 
(For how long did s/he have dysphagia before death?) 
O   Số tháng (Months)   
O    
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
26.2 
B  khó nuốt khi ăn th c ăn r n hay th c ăn lỏng hay cả 
hai loại th c ăn trên? 
(Did s/he have difficulty while swallowing solids or liquids 
or both?) 
O   1. Th c ăn r n (Solids) 
O   2. Th c ăn lỏng (Liquids) 
O   3. Cả hai (Both) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
27 
( gười mất) có b  đau khi nuốt không? 
(Did s/he have pain while swallowing?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
28 
( gười mất) có b  đau bụng không? 
(Did s/he have abdominal pain?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 2  ↓ 
Skip 29 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
28.1 
( gười mất) b  đau bụng trư c khi mất bao lâu? 
(For how long did s/he have abdominal pain before death?) 
O   Số ngày (Days)  
O   Số giờ  (Hours)  
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
28.2 
B  đau bụng trên hay bụng dư i? 
(Did s/he have upper or lower abdominal pain?) 
 
O   1. Đau bụng trên (Upper abdominal pain) 
O   2. Đau bụng dư i (Lower abdominal pain) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
29 
( gười mất) có b  chư ng bụng không? 
(Did s/he have abdominal distension?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 30 ↓ 
 Skip 30 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
29.1 
( gười mất) b  chư ng bụng bao lâu trư c khi chết? 
(For how long did s/he have abdominal distension before 
death?) 
O   Số tháng (Months)  
O   Số ngày (Days)   
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
29.2 
( gười mất) b  chư ng bụng lên có nhanh không? 
(Did the distension develop rapidly within day?) 
O   1. Nhanh (Rapidly) 
O   2. Chậm (Gradually) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
30 
( gười mất) có cảm thấy có khối c ng trong bụng không? 
(Did s/he have any mass in the abdomen?) 
 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 31 ↓ 
Skip 31 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
30.1 
( gười mất) cảm thấy có khối c ng trong bụng từ bao 
lâu trư c khi mất? 
(For how long did s/he have abdominal mass before 
death?) 
O   Số tháng (Months)  
O   Số ngày (Days)   
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
31 
( gười mất) có b  đau đ u không? 
(Did s/he have a headache?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 32 ↓ 
Skip 32 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
31.1 ( gười mất) b  đau đ u trư c khi mất bao lâu? O   Số ngày (Days)  
 100 
(For how long did s/he have headache before death?) O   Số giờ  (Months)   
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
31.2 
Cơn đau đ u đến nhanh hay chậm? 
(Did the headache develop rapidly or gradually?) 
O   1. Nhanh (Rapidly) 
O   2. Chậm (Gradually)  
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
32 
( gười mất) có b  c ng cổ không? 
(Did s/he have stiff neck?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 33 ↓ 
Skip   ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
32.1 
( gười mất) b  c ng cổ trư c khi mất bao lâu? 
(For how long did s/he have stiff neck?) 
O   Số tháng (Months)     
O   Số ngày (Days)   
O 
  99. Không biết/Không trả lời(Don’t know/ No 
answer) 
33 
( gười mất) có những lúc b  hôn mê/ mất ý th c/ không 
biết gì không? 
(Did s/he have unconsciousness?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 34 ↓ 
Skip 34 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
33.1 
Giai đoạn b  hôn mê/mất ý th c/không biết gì b t đ u đột 
ngột hay từ từ?  
(Did the unconsciousnession start suddenly or quickly?) 
O   1. Đột ngột (Suddenly) 
O   2. Từ từ (Quickly) 
O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
33.2 
Giai đoạn b  hôn mê/mất ý th c/không biết gì k o dài 
bao lâu? 
(For how long did s/he have unconsciousness?) 
O   Số ngày (Days)  
O   Số giờ (Hours)   
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
33.3 
Giai đoạn ấy có k o dài t i lúc mất không? 
(Did the unconsciousness last until death?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
34 
Trong khoảng 3 tháng trư c khi chết (Người mất) có khi 
nào b  lú lẫn không? 
(Did s/he have metal confusion three months before 
death?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 35 ↓ 
Skip 35 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
34.1 
Giai đoạn b  lú lẫn k o dài bao lâu? 
(For how long did s/he have metal confusion?) 
(Did the unconsciousness/metal confusion start suddenly or 
quickly?) 
O   Số tháng (Days)  
O   Số ngày (Months)  
O   Số giờ (Hours)   
O 
  99. Không biết/Không trả lời 
(Don’t know/  o answer) 
34.2 
Giai đoạn b  lú lẫn b t đ u đột ngột hay từ từ? 
(Did the metal confusion start suddenly or quickly?) 
O   1. Đột ngột (Suddenly) 
O   2. Từ từ (Gradually) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
35 
Trong khoảng 3 tháng trư c khi mất (Người mất) có những 
lúc b  mất tr  nh  không? 
(Did s/he have memory loss three months before death?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời 
 (Don’t know/  o answer) 
36 
( gười mất) có b  co giật không? 
(Did s/he have convulsions?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 37 ↓ 
Skip 37 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
36.1 
Thời gian co giật k o dài bao lâu? 
(For how long did s/he have convulsion?) 
O   Số giờ (Hour)    
O   Số phút  (  
O   99. Không biết/Không trả lời  
 101 
(Don’t know/  o answer) 
36.2 
( gười mất) có b  hôn mê/không biết gì ngay sau khi b  
co giật không? 
(Did s/he have comma/lost of consciousness after 
convulsion?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/ No answer) 
37 
( gười mất) có b  liệt không? 
(Did s//he have paralysis?) 
O   1. Có (Yes) 
O   2. Không (No) 
 huy n 38 ↓ 
Skip 38 ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
37.1 
( gười mất) b  liệt bao lâu trư c khi mất?  
(For how long did she have paralysis before death?) 
 
O   Số năm (Years)  
O   Số tháng (Months)  
O    
O 
  99. Không biết/Không trả lời  
(Don’t know/ No answer) 
37.2 
Nếu có, b  liệt ở đâu? 
(If Yes, where did s/he have paralysis?) 
 
Đọc những lựa chọn ở bên theo thứ tự và ĐÁ H DẤU TẤT 
 Ả  HỮ G ĐIỀU ĐÚ G 
 
(Read the answer options in the column next) 
 
1. Phía bên phải (ch n và ta )  
Righ side (both leg and hand) 
 
2. Phía bên trái (chân và tay) 
Left side (both leg and hand) 
   3. Phần dưới cơ thể (Lower part of the bod ) 
 
3. Phần trên cơ thể  
(Upper part of the body) 
   5.  hỉ một ch n (One leg onl ) 
   6.  hỉ một ta  (One hand onl ) 
   7.  ả người (Whole bod ) 
   8. Chỗ khác, nêu rõ (Other, specify)   
 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
38 
ĐTV tự x c định:  ếu người mất là  
(Data collector identif  if the deceased is ) 
O   1. Nữ (Female) 
 huy n Phần    ↓ 
Skip part 9 ↓ 
O   2. Nam (Male) 
 huy n Phần 1  ↓ 
Skip part 10 ↓ 
  
P    9: N ữ        ỏi          p ụ  ữ 
 (Questions if the deceased was female)  
  
39 
( gười mất) có b  sưng ho c u ở ng c không? 
(Did she have a tumor in the chest/breast?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
40 
( gười mất) có b  vết viêm lo t/ ung nh t ở ng c không? 
(Did she have an ulcer in the chest/breast?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
41 
( gười mất) có b  chảy máu âm đạo ngoài thời gian b  hành 
kinh không? 
(Did she have vaginal bleeding apart from the menstrual 
periods?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
42 
( gười mất) có b  chảy máu âm đạo sau khi mãn kinh 
không?  
(Did she have vaginal bleeding after menopause?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
43 
( gười mất) có b  chảy máu âm đạo nhiều trong vòng một 
tu n trư c khi mất không? 
(Did she have excessive vaginal bleeding one week before 
death?) 
O   1. Có (Yes) 
O   2. Không (No) 
O 
  9. Không biết/Không trả lời  
(Don’t know/  o answer) 
  
P    1 : M     ,        ợ               lá 
 (Part 10: Heroin addition, alcoholic addition and smoking)  
44 ( gười mất) có hút thuốc lá/thuốc lào không? O   1. Có (Yes) 
 102 
 (Did s/he smoke?) O   2. Không (No) 
 huy n 45 ↓ 
Skip 45 ↓ 
O   3. Có hút nhưng đã bỏ 
O 
  9. Không biết/Không trả lời 
(Don’t know/ No answer) 
44.1 
( gười mất) hút bao nhiêu điếu thuốc một ngày? 
(How many cigarettes did s/he smoke a day?) 
O   Số điếu (Quanlity)  
O 
  99. Không biết/Không trả lời  
(Don’t know/  o answer) 
45 
( gười mất) có uống bia rượu không? 
(Did s/he drink wine or beer?) 
O   1. Có (Yes) 
O   2. Không (No) 
Kết th c↓ 
 End ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/ No answer) 
45.1 
Trong vòng 12 tháng trư c khi chết,  
(người mất) có uống bia rượu thường xuyên không? 
Did s/he drink wine/beer during 12 months before death? 
 
(gợi ý nếu c n thiết) 
(Suggestions if necessary) 
O   1. Hàng ngày (Everyday) 
O 
2. Ba hay bốn l n một tu n  
(Three times or four time per week) 
O 
3. Một hay hai l n một tu n 
(Once or twice a week) 
O 
4. Khoảng 2 hay 3 l n một tháng  
(Twice or three times a week) 
O 
5. Khoảng một l n một tháng 
(Once a month) 
O 
6. Khoảng 6 đến 11 l n một năm 
(Six times to eleven times a year) 
O 
7. Từ 1 đến 5 l n một năm 
(Once to five times a year) 
O 
8. Không biết/Không trả lời  
(Don’t know/  o answer) 
46 
( gười mất) có sử dụng ma túy không? 
(Did s/he use heroin?) 
O   1. Có (Yes) 
O   2. Không (No) 
Kết th c↓ 
 E   ↓ O 
  9. Không biết/Không trả lời 
(Don’t know/  o answer) 
46.1 
( gười mất) sử dụng ma túy như thế nào? 
(How did s/he use heroin?) 
O   1. H t (inhale) 
O   2. Tiêm ch ch (injecting) 
Kết th c↓ 
 E   ↓ 
O   3. Cả hai đường trên (both) 
O 
  4. Không biết/Không trả lời 
(Don’t know/  o answer) 
46.2 
Trong ngày bệnh nhân chết có sử dụng ma túy không? 
(Did s/he use heroin at the day of death?) 
O   1. Có (Yes) 
O   2. Không (No) 
Kết th c↓ 
 E   ↓ O 
  3. Không biết/không trả lời 
(Don’t know/  o answer) 
KẾT THÚ  PHỎN   ẤN (End of the interview) 
